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ABSTRACT 
Ruthenium (Ru) complexes have captivated an increasing interest in recent 
years; they are a promising alternative to platinum-based complexes due to the 
fact that some of them have been repeatedly described for showing higher 
selectivity and lower cytotoxicity regarding their effects on cancer cells. 
The interactions studied between the Ru-complexes and serum proteins such as 
fatty acid free Human Serum Albumin (fafHSA) are of very high importance 
considering that their bioavailability and effects depend on their binding to 
albumin to reach the targeted cells. In addition, the Food and Drug 
Administration (FDA) has set the report on plasma protein binding for prodrugs 
as a requirement in order to do the screening for potential therapeutic agents. 
The interactions and several aspects related to the binding between the 
ruthenium (II) complex [RuII(Cp)(bipy)(CO)][PF6] (or RuC, also named pmc44) 
and HSA are addressed using fluorescence spectroscopy, steady-state and time-
resolved measurements, and UV-Visible absorption in 10 mM HEPES buffered 
medium pH 7,4. Additionally, in order to obtain a deeper insight into the HSA 
binding properties of the complex at the specific drug binding sites, 
displacement experiments with the site markers Warfarin and Dansylglycine (for 
which the binding site is well known) were performed. 
The results show that the complex strongly quenches the intrinsic fluorescence 
of albumin and that the interaction is quite fast, indicating that the complex 
successfully binds the protein. The outcome from the Stern-volmer linearizations 
(both time-resolved and steady-state measurements) displayed more than one 
type of quenching mechanism; albumin fluorescence is quenched by a 
combination of dynamic and static quenching mechanisms. The most 
representative values obtained for KD and KS from the averages were (4,8 ± 
0,3)x104 M-1 and (2,3 ± 0,7)x104 M-1 respectively, calculated with the Stern-
Volmer linearization at em=338 nm by a Minimum Square Fit procedure with 
variance analysis (ANOVA) with a 95% confidence level. 
A speciation model with two protein-RuC adducts is proposed with global 
conditional binding constants of log β’1= (4,78 ± 0,01) (for the 1:1 adduct {HSA-
RuC}) and log β’2= (9,52 ± 0,01) (for the 1:2 adduct {HSA-(RuC)2} with a fitting 
parameter of 1,16x105 using the computer program PSEQUAD. 
The conclusions achieved with the site markers´ experiments revealed that the 
complex binds to both sites I and II of the protein.  
Altogether, the results from this work indicated that the complex studied can 
bind human serum albumin in a moderate way and thus it be efficiently 
transported in the blood by HSA. 
KEYWORDS: Cancer therapy, human serum albumin, fluorescence spectroscopy, 
ruthenium complexes, ruthenium, UV-Vis absorbance, binding site.  
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RESUMO 
 
O Cancro é a segunda maior causa de morte em países desenvolvidos. Estima-se 
que o número global de mortes por cancro aumente em 50% até 2030, criando a 
necessidade urgente de encontrar soluções para este problema de saúde global. 
A cisplatina, carboplatina e oxaliplatina são os únicos metalofármacos aprovados 
para uso clínico em todo o mundo mas, apesar da sua eficácia, apresentam 
efeitos secundários que limitam muito a sua utilização. 
 
Os compostos de ruténio são já reconhecidos como uma alternativa promissora 
aos fármacos de platina usados em quimioterapia, dada a sua menor citotoxidade 
e maior selectividade. Além disso, oferecem diferentes mecanismos de acção e 
um espectro de atividade diferente, mais alargado, que os metalofármacos de Pt. 
O seu mecanismo de acção é intensamente estudado actualmente e a ligação a 
proteínas séricas parece ter um papel importante na sua resposta biológica. 
 
O estudo da interacção com proteínas séricas e com a albumina do plasma 
humano (HSA) em particular reveste-se de uma grande importância no contexto 
do desenvolvimento de metalofármacos. Por um lado, a interacção com a 
albumina tem um impacto importante na biodisponibilidade do complexo em 
estudo. Por outro lado, a HSA desempenha um papel fulcral no transporte de 
compostos endógenos e exógenos, sendo também crucial como veiculo 
transportador de compostos terapêuticos para lhe permitir atingir as células e 
tecidos-alvo onde exercem a sua acção. Além disso, é um requisito da FDA (Food 
and Drug Administration) que resultados da interacção com proteínas séricas 
sejam incluídos no processo de pre-selecção de potenciais fármacos e 
metalofármacos.      
Neste trabalho estudou-se a interacção de um complexo organometálico de 
ruténio(II) de estrutura em banco de piano com a albumina de plasma humano 
(sem ácidos gordos, fafHSA). O complexo [RuII(Cp)(bipy)(CO)][PF6] (designado 
neste trabalho por RuC), com uma actividade moderada para o adenocarcinoma 
de ovário humano, é solúvel em água o que o torna muito interessante no 
contexto de desenvolvimento de novos agentes terapêuticos. A sua ligação à HSA 
foi estudada em meio aquoso a pH 7.4 (tamponizado com HEPES) e à 
temperatura de 37ºC por espectroscopia de UV-Vis e espectroscopia de 
Fluorescência (em estado estacionário e resolvida no tempo) usando a emissão 
do resíduo Trp214 da proteína como sonda de fluorescência intrínseca. 
A interacção do complexo com a HSA ocorre rapidamente e resulta na extinção 
da fluorescência do Trp214 por um processo misto estático e dinâmico, para o 
qual se obtiveram as constantes de Stern-Volmer KD = (4,8 ± 0,3)x104 M-1  e  KS 
=(2,3 ± 0,7)x104 M-1  (calculadas a em=338 nm pelo método dos mínimos 
quadráticos para um nível de confiança de 95%). 
O modelo proposto para a interacção RuC–HSA engloba a formação de dois 
aductos complexo-proteína de estequiometrias 1:1 e 1:2 para os quais são 
calculadas constantes de formação condicionais log β’1= (4,78 ± 0,01) (para o 
aducto 1:1 {HSA-RuC}) e log β’2= (9,52 ± 0,01) (para o aducto 1:2 {HSA-(RuC)2}. 
XV 
 
Reacções de competição com “marcadores” conhecidos como a varfarina e a 
dansilglicina, para os quais a ligação à HSA é específica e está bem estudada, são 
utilizadas para obter informação sobre os locais de ligação do RuC à proteína.  
Os resultados obtidos neste trabalho permitem concluir que o complexo 
organometálico estudado interactua com a HSA de forma moderada, podendo ser 
eficientemente transportado pelo sangue através da ligação a esta proteína. 
PALAVRAS-CHAVE: Cancro, albumina do plasma humano, Ruténio(II), 
complexos de Ru(Cp),  espectroscopia de fluorescência, locais de ligação, 
biodisponibilidade.   
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1.0. INTRODUCTION 
 
1.1.0.   Cancer conditions 
 
According to the World Health Organisation (WHO) Cancer is one of the most 
important causes of death worldwide. The figures show 8.2 million of deaths in 
2012, numbers that are expected to rise from 14 to 22 million annual cases 
within the next two decades 1. 
 
Cancer is characterised by the rapid and uncontrolled growth of cells (abnormal 
cells) that invade nearby tissues, and eventually spread to vital organs. This later 
process is known as metastasis and it is started by genetic alterations and 
mutations in cells. Figure 1 represents the main stages involved in the 
progression of a malignant tumour to an invasive cancer (condition) 2. 
 
 
Figure 1. Metastasis development: A malignant tumour expands across time as shown above as a 
consequence of four mutations. a. A cell undergoes a genetic mutation leading to abnormal 
growth. b. Hyperplasia is the rapid division and growth of the mutated cell and its descendants. c. 
Dysplasia is when the cell’s descendants look abnormal and divide at a fast rate. d. In situ cancer: 
the tumour that has been assembled with these cells remains in the original tissue. e. If the cells 
suffer further mutations and the tumour infest nearby tissues depositing cells into the lymph or 
blood the tumour is said to be malignant. The escaped cells are very likely to form new tumours 
in other parts of the body (metastasis) (modified from ref 3). 
 
Currently cancer treatment is limited to radiotherapy, surgery and use of 
cytotoxic agents, which are known for their problems associated with the 
development of resistance and side effects 4. The treatment for metastasis is yet 
to be found because it is the most important target to defeat regarding cancer. 
Cisplatin became in 2001 the gold standard treatment in combination with 
radiotherapy against cervical cancer. It still plays nowadays a central role in 
cancer chemotherapy despite its toxicity and, it is used as first line 
chemotherapy against several epithelial malignancies. In addition to this, it is 
used as second and third line treatment against few metastatic malignancies 
including cancers such as breast, prostate and melanoma to name a few. The 
response rate for chemotherapy in most advanced cancers is approximately 15% 
in second and third line treatments and about 50% in first line treatments. There 
are examples of some other treatments that use a combination of cisplatin or 
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carboplatin with radiotherapy and other drugs such as gemcitabine or taxanes 
that increase the response rate up to 80% 5.  
Cisplatin (cis-dichlorodiammineplatinum(II)) or CDDP (Figure 2) was the first 
platinum-containing complex used to treat cancer and Rosenberg described its 
inhibitory activity on the division of Escherichia coli 120 years after its synthesis 
6. In 1968, cisplatin was successfully tested in mice, three years later, phase I 
trials (first patients) began and was FDA approved for use in 1978. The 
discovery of severe safety issues derived from the treatment with cisplatin 
(nephrotoxicity) led to the biological evaluation and synthesis of many cisplatin 
analogues and other elements. Subsequently, the effort was made aiming at 
making cisplatin-based drugs safer to patients 7. 
 
Although metal ions were used in medicine already, cisplatin was a very 
important discovery because prior to this date all cancer treatments where 
focused on organic molecules. From this achievement, cancer research focused 
on metallodrugs.  
 
Cisplatin’s mode of action has been well studied since its discovery. It was 
suggested that more than 90% of platinum in the blood after its intravenous 
administration was covalently bound to the plasma proteins. Thus, the study of 
the binding cisplatin-protein was of a greater interest than the binding regarding 
cisplatin-DNA. It is known that once the drug has entered the cell, it was found to 
bind HSA at C-N and S-H groups. These drugs bind to the Cys-34 as well as to the 
Met-298 of the protein, causing important conformational changes, which result 
in considerable perturbations of the amide I and amide II vibrational frequencies 
8.   
 
This discovery provoked a high interest in platinum (II) compounds as potential 
anticancer drugs and many patients with different types of cancer have been 
successfully treated with CDDP. Due to the success in the clinical use, patients 
with cancers including: sarcoma, bones, muscles, soft tissue and blood vessels 
receive a better prognostication and a higher hope for recovery nowadays. These 
achievements stimulated the search for new platinum derivatives 9,10. 
 
Apart from cisplatin, there are other complexes currently approved for clinical 
use worldwide: Carboplatin, Oxaliplatin and Nedaplatin (Figure 2). Carboplatin 
and cisplatin are less toxic than cisplatin. Oxaliplatin is highly efficient against 
colorectal cancer. Nedaplatin is exclusively used in Japan head, neck, testicular, 
lung, oesophageal, ovarian and cervical cancer. Despite the improvements, these 
complexes still have to overcome the acquired tumour resistance that they 
present 10,11. 
 
Figure 2. Structure of four platinum derivatives clinically in use (modified from ref 10). 
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Concerning the advantages and disadvantages of using platinum drugs, has to be 
said that: they are highly effective but only on a limited number of cancer 
conditions, their side effects are highly debilitating due to their high toxicity 
which are the major drawbacks (nephrotoxicity), these drawbacks may be 
overcome with alternative treatments, alternative agents with different modes of 
action that bypass the resistance mechanisms activated in Pt-based treatment. 
 
The greatest challenge in designing anti-cancer drugs is the improvement of the 
selectivity because even though these anti-cancer drugs are generally cytotoxic, 
they are also a threat to healthy or normal cells, which is why side effects are 
repeatedly serious. 
 
Due to the fact that cisplatin is highly toxic, the principal objective during many 
years has been to accomplish new chemotherapeutic compounds with less 
toxicity and greater efficacy, metallodrugs with other mechanisms of action 10. 
Consequently, the pursuit for alternative therapies has led to the synthesis of 
new anticancer drugs with metals such as Ruthenium.  
 
1.2.0. Ruthenium complexes 
 
Research on ruthenium-containing compounds as anticancer agents has had the 
goal to overcome the limitations of platinum compounds against cancer cell 
lines. The fact that they show fewer side effects and that they can be found in 
different oxidation states biologically accessible (II, III and IV) under suited 
conditions, places them in a very well position as potential substitutes. Apart 
from these, other benefits have demonstrated their potential: (i) the low energy 
barriers for the transformation between these oxidation states permit ready 
oxidation state changes within the cell; (ii) octahedral coordinated complexes in 
contrast to the square-planar geometry of platinum(II), involving two extra 
ligands in its structure to operate on a different manner from cisplatin 
compounds; (iii) the possibility of slow ligand exchange rates in water (Figure 3), 
which kinetics are on the cellular reproduction timescale (mitosis). This 
implicated that if a ruthenium ion establishes any interaction with any 
component present in the cell, it is possible to continue bound to it for the rest of 
the cell’s lifetime; (iv) ruthenium’s ability of performing alike iron in binding 
establishing to biomolecules, such as Albumin or Transferrin is a very important 
advantage to become less toxic than platinum drugs.12, 13 
 
Figure 3. Logarithmic presentation of relative kinetics of aqua ligand exchange for different 
metal ions, ruthenium shows a relative low rate (modified from ref 14). 
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In order to explain the lower toxicity of Ruthenium complexes in comparison 
with Platinum compounds the “activation by reduction” mechanism is to be 
mentioned. This mechanism works selectively in solid tumours with low oxygen 
level (hypoxia), which generates a reducing environment enabling the reduction 
of Ru (III) to the more reactive Ru (II) species. Tumours grow at a rapid rate due 
to the deficient formation of new blood vessels and blood supply. The low pH 
outside the cell, the low oxygen level and the existence of cellular reducing 
agents contribute to the conditions for the selective reduction of drugs with 
RuIII/RuII redox potential. This reducing ability of ruthenium (III) compounds 
relies on the ligands in the structure. Knowing the net electron donation from 
ligands to metals helps to predict metal-centred redox potentials and therefore 
drugs with the desired redox parameters can be obtained. Nonetheless, Ru (III) 
complexes can undergo hydrolysis or bind to proteins prior to reduction and 
alter their redox properties 14-17. Despite the existing wide range of information 
the mechanism of action of Ru-based anti-tumour agents is still under study. 
 
The first ruthenium complexes that have successfully undergone clinical trials 
are KP1019, indazolium [trans-tetrachlorobis(1 H-indazole)ruthenate(III)] and 
NAMI-A, imidazolium [trans-tetrachloro(dimethylsulfoxide)-
imidazoleruthenate(III)] (Figure 4) 18.  
 
Figure 4. Chemical structure of two ruthenium complexes that have successfully completed 
phase I clinical trials (modified from ref16). 
 
The complex NAMI-A is not very active against solid primary tumours, however, 
it shows metastasis inhibition in all the experimental models of solid tumours 
under test. This characteristic is noticeably important because despite the 
progression in the treatment of primary tumours, metastasis still represents a 
big challenge in cancer treatment for being the main cause of the death. The 
cytotoxic activity of NAMI-A against metastasis seems to be related primarily 
with its antiangiogenic (reducing the growth of new blood vessels) potential. 
Nonetheless, its capacity to remodel at cytosqueleton level and its ability to alter 
the cellular adherence are also important 15-17, 19. 
 
The second complex above-mentioned, KP1019, is substantially active against 
cisplatin resistant colon carcinoma and some primary explanted tumours. It is 
believed that the protein Transferrin transports the compound until it reaches 
the targeted cells, after this, the complex is released in the endosomes at acid pH 
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causing apoptosis through the mitochondrial pathway. In addition, this complex 
has shown a much moderated toxicity, which is practically non-existent in the 
clinical trials that it has undergone 14-17.  
 
The complexes mentioned above are Ru(III) compounds with monodentate 
ligands and it is thought that their mechanism of action entails the reduction to 
Ru(II), which are more active compounds. Because of this, the interest for the 
anticancer abilities of Ru(II) complexes has increased 20.  
 
The fact that some Ru-agents are anti-metastatic is one of their most interesting, 
promising and unique features. Their mechanism of action is proposed to involve 
serum proteins, therefore, albumin binding is determinant in the bioavailability 
of the compound and it is also a requirement of the FDA in the drug development 
process 21.  
 
Possibily the major group of Ru(II) compounds reported as potential 
metallodrugs are ‘Ru(arene)’ organometallic mononuclear piano-stool 
complexes.  
 
RAPTA (Ruthenium-Arene-PTA) complexes comprise a promising family of 
organometallic compounds in this context (PTA is 1,3,5-triaza-7-
phosphaadamantane). There are some RAPTA complexes with anti-metastatic 
properties such as RAPTA-T [Ru(phenanthroline)(κ-C,N-(2-(2-phenyl-pyridine) 
(NCMe)2][PF6] (with a piano-stool geometry), that alike the other derivatives of 
this family has weak cytotoxicity. However, its cytotoxicity is better expressed on 
tumour cells than in healthy cells. At the same time that shows an important 
ability to modify the behaviour of cells concerning metastasis and invasion. In 
some occasions RAPTA-T acted like RAPTA-C ([Ru(η6-C10H14)(PTA)Cl2]) showing 
some activity in vivo in a model of solid metastasizing tumours 15. Even though 
the metastases reduction is moderate and it is only evident at certain doses, 
these effects of the family of RAPTAs on metastasizing tumorous that appear 
spontaneously are very important as it is the first evidence for another 
ruthenium-based complex to show some selectivity of anti-tumour activity 
against metastases 15. 
 
Not many studies in the literature have addressed complexes with the Ru(II)-
cyclopentadienyl moiety (Ru(η5-C5H5) or Ru(Cp), isoelectronic with Ru(arene)). 
The potential of these derivatives in the field of metallodrugs were first reported 
for [Ru(η5-C5H5)CO’pyridocarbazole’] compounds that exposed strong and 
selective inhibitors of protein kinases GSK-3 and Pim-1 22, 23. Exceptional results 
have been consistently found for a few other families of Ru(Cp) compounds 
developed at Faculdade de Ciências, Universidade de Lisboa by the research 
group of Quimica Organometálica e Biorganometálica.  
 
1.2.1 Ruthenium cyclopentadienyl complexes 
 
Several Ru(Cp) complexes presented potent cytotoxicity against a wide range of 
human tumour cell lines 24-26. The first members of this {RuII(Cp)} family had 
general formulas of [Ru(Cp)(PPh3)2L]+ or [Ru(Cp)(PP)L]+ (L being a 
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monodentate N-heterocycle ligand, PPh3 being a monodentate 
thiphenylphosphane and PP a bidentate phosphane ligand) 21. These complexes 
exhibited high cytotoxicity against LoVo human colon adenocarcinoma, Mia Paca 
pancreatic cells and human promyelocytic leukemia HL-60 cells 24, 21. These 
complexes reported by M. Helena Garcia workgroup have no labile Cl- co-ligand, 
which is distinctive feature from most of the organometallic Ru complexes 
reported. This family of compounds revealed strong cytotoxicity against several 
human tumour cell lines with IC50 values in the sub-micromolar range, much 
lower than those found for cisplatin 21, 24-28. 
 
Aiming at accomplishing enhanced chemical stability, a different family was 
synthesized with the general formula [Ru(Cp)(LL)(PPh3)]+, where LL is a 
bidentate ligand. Very promising antitumour features were identified for some 
complexes, especially for the complex [RuII(η5-C5H5)(bipy)(PPh3)]+ (Figure 5) (or 
TM34, PPh3 is the monodentate triphenylphosphane). TM34 is composed by a 
bidentate quelated ligand (2,2´ bipyridyl binding Ru(II) through its two Npyridine 
atoms) and the cyclopentadienyl ligand.  This compound was found to be 
chemically very stable in aqueous media and in strong coordinating solvents. A 
very low amount of a co-solvent (DMSO, 2%) was needed to attain full solubility 
in pH 7,4 buffered aqueous media and overcome its lack of solubility in water 21. 
 
Figure 5. Structure of the Ru(II) complex TM34 (modified from ref21). 
 
TM34 exhibited exceptionally high activity against cisplatin resistant tumour cell 
lines such as e.g. resistant ovarian adenocarcinoma, breast cancer and grade IV 
prostate cancer. It was also very active against cisplatin sensitive cells: this 
complex was found to be approximately 15 times more active against A2780 
than cisplatin. Its mechanism of action is not yet fully known. It might involve the 
inhibition of key enzymes in the cell such as poly(ADP-ribose) polymerase 1 
(PARP-1) as it has been also proposed for other non-platinum complexes (e.g. 
some gold complexes) 21 . In fact, TM34 is the strongest inhibitor agent disclosed 
for PARP-1, with IC50 values surpassing those described for cisplatin (CisPt), 
NAMI-A and RAPTA-T. This complex is also expected to be transported by 
albumin (HSA) in the blood stream with no loss of activity since the HSA adduct 
formed kept the complex cytotoxicity fairly unchanged 21.  
 
Electrospray ionization mass spectrometry was useful to understand how tightly 
the different co-ligands were bound to Ru(II) in these Ru(Cp) complexes 29. 
These results indicated that the {Ru(Cp)} moiety was rather robust and very 
stable, while the complexes lost their less tightly bound ligands with some ease. 
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In TM34 bearing the bidentate bipy, the co-ligand less tightly bound to Ru(II) 
was PPh3 followed by bipy, with the {Ru(Cp)} remaining intact.   
 
The effect that changes in the bipyridyl ligand would have on the biological 
activity of TM34 was also reported. Excellent results were obtained for the 
complex [RuII(η5-C5H5)(PPh3) (Me2bpy)][CF3SO3] (Figure 6) (Me2bpy being 4,4’-
dimethyl-2,2’-bipyridine)28. This complex showed remarkable cytotoxic activity 
displaying IC50 values in the nanomolar and sub-micromolar range, again largely 
surpassing the activity of CisPt in several tumour cell lines studied, including 
quite aggressive CisPt resistant cells such as the grade IV prostate cancer cells 
(androgen independent) and highly invasive breast cancer cells (estrogen 
independent). As observed with TM34, the activity of this complex was not 
affected by its binding to human serum albumin28.  
 
 
Figure 6. Structure of the ruthenium complex [RuII(η5-C5H5(PPh3)(Me2bpy)][CF3SO3] (modified 
from ref28) 
 
Using TM34 as a structural unit, a polymeric controlled drug delivery vehicle was 
synthesized as an alternative to the conventional drug delivery in cancer 
therapy. A mononuclear {Ru(Cp)} derivative merged with a polymeric unit was 
achieved in [RuII(Cp)(Ph3)(bpyPLA)][CF3SO3] (bpyPLA being 2,2′-bipyridine-
4,4′-D-glucose end-capped polylactide, a  biocompatible polymer linked to bipy) 
(Figure 7) 30. This RuPMC (Ruthenium Polymer Metal Complex) compound, 
although less active than TM34, still exhibited cytotoxicity in the micromolar 
range against human tumour cell lines with different response to cisplatin, with 
IC50 values surpassing (or in the same range as) those reported for CisPt 
. 
Figure 7. Structure of [RuII(Cp)(Ph3)(bpyPLA)][CF3SO3], the first RuPMC reported which was 
inspired on TM34 and is highly active against human ovary and breast adenocarcinomas 30. 
 
Therefore, the complexes of this family are demonstrating to be great potential 
chemotherapeutic drugs in in vitro assays with human tumour cell lines. 
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1.2.2 The complex [RuII(η5-C5H5)(bipy)(CO)][PF6] 
 
The group of Quimica Organometálica e Biorganometálica from Faculdade de 
Ciências, Universidade de Lisboa coordinated by Prof. M. Helena Garcia has 
obtained excellent results with the piano-stool ruthenium(II) complexes 
developed so far. 
 
A new Ru(Cp) complex [RuII(η5-C5H5)(bipy)(CO)][PF6] (or pmc44) was recently 
prepared, and presently being screened for its potential as a chemotherapeutic 
agent for cancer therapy. This new member of the {Ru(II)Cp} family, which is 
denominated throughout this work as RuC, contains in its structure the bipy 
ligand and a carbon monoxide (CO) (Figure 8). In fact, the only difference 
between RuC and TM34 is the CO ligand replacing the triphenylphosphane 
(PPh3). The rationale for preparing this complex was to combine the therapeutic 
effect of carbon monoxide with the [Ru(Cp)(bipy)]+ core that has proven to be 
very cytotoxic for cancer cells. 
 
Figure 8. Structure of the complex [RuII(η5-C5H5)(bipy)(CO)][PF6] (RuC) studied. 
 
Indeed, evidence for the beneficial effects of CO have been consistently building 
up, with preclinical studies showing the favourable effects of CO in 
cardiovascular disease, sepsis and shock, cancer, acute and chronic rejection of a 
transplanted organ, and acute lung, kidney and liver injury 27.  The interest of CO 
as a ligand is that its unique chemistry reacting exclusively with transition 
metals is a great advantage for using it as a therapeutic stem. Its chemistry is also 
varied and highly versatile. The two most-studied CO-based pharmaceuticals are 
stable and fully water soluble, which are two of the properties expected for the 
complex studied in this work 27.  
 
Although results for the complex RuC are still being gathered, some were already 
available when the work in this thesis was executed, and are collected in the 
following paragraphs.  
 
The structure of RuC and the results previously obtained for TM34 anticipated 
high chemical stability in solution for this complex. Bipy is well-known as an 
excellent bidentate chelating ligand that allows electron back-donation due to its 
low lying energy orbitals (π* empty). It has been extensively used as a building 
block in supramolecular/macromolecular chemistry and in nanoscience 31. The 
two Npyridine donor atoms are very effective in Ru(II) coordination, and form a 
stable 5-membered chelate ring when coordinated to the metal ion. The Ru(Cp) 
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core is quite stable too, and carbon monoxide coordinates to the Ru(Cp) moiety 
quite strongly as was observed when characterizing 32. 
 
RuC is soluble in water with no need for an organic co-solvent, and this is a 
feature desirable for an easier and effective drug formulation. Its partition 
coefficient in a water/octanol system (adopted as a rough model for the cell 
membrane), log Po/w value was -0.66, which means that the complex is 
hydrophilic (Log Po/w = Log {[complex(org)]/[complex(aq)]}). Being soluble in water 
is quite important for drug development.  
 
In what concerns activity, the cytotoxicity of the prospective drug RuC was 
determined in the human tumour cell line A2780 (ovarian carcinoma, 
cisplatin sensitive). Cell viability was determined using the well-established MTT 
assay (MTT = [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide])33, 
after a 72 h exposure and the cytotoxic effect of the compound was quantified by 
calculating the IC50 value (the drug concentration inhibiting tumour cell growth 
by 50%). A preliminary value of IC50=(49±12) µM was measured which is 
moderate compared to the results of other ruthenium complexes or CisPt (Dr. 
Andreia Valente, private communication).  
 
Experiments to evaluate whether the binding of RuC to albumin (fafHSA) would 
influence the cytotoxic activity of RuC in A2780 cells were also executed. Results 
indicated that albumin binding does not affect RuC activity in comparison to the 
compound alone, yielding adducts that maintain the same cytotoxic properties 
(Dr. Andreia Valente, private communication). 
 
Cell assays are currently being executed on healthy cells to evaluate if the 
complex has some intrinsic selectivity for cancer cells against healthy cells. 
 
RuC is thus not as highly active as other members of the family, especially TM34. 
Nevertheless, the water solubility and the lower activity can be important 
requirements to obtain a metallodrug with a more controlled and selective effect 
on the target (tumor) tissues. 
 
1.3.0. Blood Serum: Components 
 
Drug delivery is directly dependant on the blood transport. In fact, blood is the 
most important vehicle for the transport of drugs from the administration site to 
the targeted spot of action. In addition, serum and its components might modify 
the compound structure and affect its delivery to the target 34.  
 
Blood consists of cellular and non-cellular parts. The non-cellular part or plasma 
contains 90% of water; the rest 10% are dissolved substances such as, proteins 
(CHSA ~ 630 μM), nutrients, hormones, electrolytes and metabolites. Blood serum 
is distinguished from blood plasma when fibrinogen and other proteins that 
stimulate coagulation are not present. In order to interpret the speciation of the 
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metal ions in plasma, it is essential to know the formation constants for the 
species assembled between them and the metal ions 35. 
 
Countless drugs have demonstrated to be bound to proteins present in plasma 
when they enter the bloodstream. The extension and strength of this interaction 
affects the circulation and delivery of the drug into other areas, as well as its 
toxic and therapeutic responses 35.  
 
The distribution of many drugs and other compounds in the body depend on 
their affinities for HSA and their binding abilities. Strong binding interactions 
between this serum protein and drug may decrease the concentration of free 
drug in plasma while weak binding interactions might lead to a short lifetime or 
poor distribution. However, if the correct binding is present, albumin can 
transport the drug bound to it to the targeted location. Therefore, the study of 
the binding interactions between serum proteins and drugs is essential in 
pharmacology and pharmacodynamics 36.  
 
1.3.1. Human Serum Albumin 
 
Human serum albumin is a globular protein that has many crucial physiological 
functions. It is the most abundant protein in plasma (35-50 g/L human serum), 
accounts for approximately 60% of total plasma protein and its molecular weight 
is 66.5 kDa. Albumin is synthesised in the liver (as nearly all plasma proteins) 
and exhibits an average half-life of 19 days. The main function of albumin is to 
transport fatty acids and apart from acting as the most important nonspecific 
transporter protein in the circulatory system, HSA is the major protein 
responsible for the colloid osmotic pressure of the blood 37- 39. 
 
This is a very soluble and robust protein, which can be heated at 60 °C for up to 
10 h without damaging its structure; it is acidic and stable in pH 4-9 and soluble 
in 40% ethanol. It is an important agent for the solubilisation of poorly water-
soluble drugs and it may also increase their half-life when they are bound to it by 
decreasing its elimination at the glomerulus. It is an excellent candidate for drug 
delivery due to the above-mentioned properties as well as for its preferential 
accumulation in tumour and inflamed tissue, its biodegradability, its ready 
availability and its lack of immunogenicity and toxicity 37. 
 
Albumin accumulates in inflamed tissue due to the “enhanced permeability and 
retention (EPR) effect” of cancer cells. In the 80´s Y. Matsumura and H. Maeda 40 
described that a polymeric protein was more active than the single product, 
concluding that this effect depends on the special vascular and lymphatic 
properties of cancer cells 40. The leaky deficient blood vessels of tumour tissue 
(with big pores) make it accessible for macromolecules, while in the blood 
vessels of healthy tissue only small molecules can cross the endothelial barrier. 
This enhanced retention of macromolecules in tumour tissue is mainly generated 
by a lack of lymphatic drainage due to a defective lymphatic system. Thus, the 
responsible for the accumulation of macromolecules in malignant tissue 
(tumours) is due to the combination of an enhanced permeability and retention 
37. Large molecules would almost selectively be taken and retained by cancer 
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cells whereas in the case of normal cells the excretion through the healthy 
lymphatic system would occur 41. 
 
Thus, albumin binding can be a means of effective transport of a metallodrug to 
its targets, it has an impact of the compound bioavailability and in vivo half-life, 
and can be a route to improve the selectivity of the prospective drug to inflamed 
and malignant tissue through passive targeting due to the EPR effect.  
 
The strength and reversibility of the binding to the serum protein is an 
important influence in the different behaviour of Pt- and Ru- metallodrugs. Pt-
based compounds are reported to have no important antitumor activity, most 
likely due to the strong irreversible binding. This is not the case for ruthenium 
compounds, since HSA plays a big role in the distribution of these compounds 
throughout the body 35.  
 
HSA is reported to play a big a role in KP1019’s mode of action. The initial 
binding of KP1019 with HSA occurs at the HSA’s hydrophobic binding sites in a 
noncovalent manner, however, the interaction slowly changes to a protein-
coordinated form after a longer incubation time. It is known that ruthenium 
complexes can bind to albumin and transferrin when they are independently 
incubated with each protein in buffer conditions, however, in the blood serum 
they show a preference for albumin. The role of protein binding is essential for 
its bioavailability as it prevents its precipitation and hydrolysis at pH 7,4 35.  
 
KP1019 is known to bind the protein with moderately strong affinity and in a 
reversible manner. Several binding constants have been reported for KP1019, 
ranging from log K’B=4,02 to log K’B=5,66, the latter using the same approach 
(and PSEQUAD program) as the one used in this thesis 35, 42.  
 
1.3.2. Structure and composition of Human Serum Albumin 
 
Albumin is a serum protein consisting of a single polypeptide chain of 585 amino 
acid residues, which are organized in three structurally similar α-helical domains 
(I, II and III) resembling a heart shape as shown in Figure 9(a). Each domain is 
additionally divided into two subdomains, A and B (Figure 9(b)) that includes six 
and four α-helices, respectively, connected by long α-helical chains 44.  
 
The stability of the 3D native structure of albumin is maintained by several 
factors such as inter- and intra-domain forces being hydrophobic interactions, 
salt bridges and natural boundaries of helical extensions present between three 
domains 44.   
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Figure 9. Graphic representation of Human Serum Albumin showing: a) tertiary structure (each 
subdomain is marked with a different colour) and b) secondary structure of HSA (disulphide 
bridges are drawn with thick lines) (modified from ref43). 
 
The protein accommodates several amino acid residues that present 
fluorescence properties, 31 phenylalanine (phen) and 18 tyrosine (tyr) residues 
and only one tryptophan (Trp214) 45. For this reason, albumin is the perfect 
candidate for fluorimetric studies because the tryptophan amino acid can be 
selectively excited at 295 nm. Tryptophan is located on the 214th position of the 
sequence and it is spatially oriented towards binding site I (Sudlow´s site I) 
within the protein. Therefore, any changes in the fluorescence properties of the 
protein are attributed to modifications in the surroundings of the tryptophan 
amino acid. 
 
Albumin is a flexible molecule that rapidly assumes different conformations. It 
could be regarded as an assembly of resilient parts frequently contracting, 
expanding and flexing through the opening and closing of major crevices under 
the influence of ligands. As a result of this constant motion of the amino acid 
chains, the molecule of albumin is well fitted to adapt or discharge the many 
substances that it transports 46. 
 
This protein is very soluble because it contains a large number of ionized amino 
acids that contribute to its high total charge. The isoelectric point of the protein, 
(which is the pH at which the net charge of a molecule is zero) is the pH at which 
the protein will not move to an electric field, for fatty acid free albumin in 0,15 M 
NaCl the isoelectric pH is about 4,7. The global charge of the protein at pH 7,4, 
which was the pH used in the measurements, is negative (-19) 46.  
 
1.3.3. Binding sites on HSA 
 
Specific interactions of drugs and their competition for binding sites on 
transport proteins might influence their distribution in serum. Therefore, 
information on the drug-HSA binding will provide a better understanding of the 
absorption and transportation of a specific drug. Structural examinations have 
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displayed specific locations of the drug binding sites on HSA affecting some 
domains or subdomains of the protein 44. Numerous drugs bind to one of the two 
primary binding sites on the protein (hydrophobic cavities) in subdomains IIA 
and IIIA, denominated Sudlow’s sites I and II, respectively (Figure 9(a)) 47. These 
are considered the main ligand binding sites on albumin 47. According to 
Sudlow´s classification, site I has been identified for the binding of large ligands 
with negative charge such as dicarboxylic acids or bulky heterocyclic molecules, 
whilst site II has been outlined by the binding of aromatic carboxylic acids such 
as non-steroidal anti-inflammatory drugs 48-50.  
 
Strong binding interactions between drugs and albumin can decrease the free 
concentration of drug in plasma, while weak binding interactions can lead to a 
poor distribution or short lifetime. Therefore, too weak or too strong binding 
between drugs and the serum protein will lead to poor drug distribution. Under 
the circumstances, it is clear that the investigation of these binding interactions 
is very important from the pharmacologic and pharmacodynamics point of view 
36, 51.  
 
1.4.0. Site markers: Warfarin and Dansylglycine 
 
Warfarin [3-(α-acetonylbenzyl)-4-hydroxycoumarin] (WF) is an anticoagulant 
drug that has been widely used to treat illnesses such as pulmonary embolism 
and venous thrombosis 52. The molecule´s structure is normally drawn like an 
open chain, however, it is generally thought to exist as a cyclic hemiketal in 
solution 53 (Figure 10). The site I is responsible for the specific binding of warfarin 
and other drugs such as azapropazone and phenylbutazone, to name a few. 
Consequently, this site is also called the warfarin-azapropazone binding site 54, 55. 
Warfarin is used as a marker ligand or competing agent to study the interactions 
of other drugs for the explicit binding to site I on HSA because under normal 
therapeutic conditions, warfarin is 99% bound to the serum protein in 
circulation 56. Warfarin binds to the site I of HSA with an apparent binding 
constant log Kb of about 5,71 or 5,79  42, 57. 
 
Dansylglycine N-[(5-dimethylamino)naphth-1-ylsulfonyl]glycine (DG) belongs to 
a class of dansylated amino acids, which are largely used as fluorescent probes 
for the characterization of the binding sites in albumin. This site marker in 
particular is a probe for the binding site II and its structure is shown in the Figure 
10 58. Dansylglycine is used as a marker ligand or competing agent to study the 
interactions of other drugs for the explicit binding to site II on HSA, it normally 
binds to the site II of HSA with an apparent binding constant log KB of about 
5,34- 5,36 35, 57. 
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Figure 10. Chemical structures of Warfarin (WF, top left) and Dansylglycine (DG, top right). 
Bottom: Warfarin displays an open side chain conformation (A) and a cyclic hemiketal 
conformation (B), which is how it is normally found in solution (modified from ref 57, 59). 
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2.0. OBJECTIVES 
 
The development of new medicines for cancer therapy is a research theme very 
appealing to me. To be able to work on this topic provides me excitement, 
motivation, and the feeling that my work will somehow contribute to achieve an 
important goal with a great impact on society and healthcare. 
 
Ruthenium complexes are a promising option to the toxic platinum-containing 
compounds available in the Clinic. Ruthenium(II) complexes bearing the {Ru(η5-
C5H5)} moiety (or{Ru(Cp)}), in particular compounds with bipyridine (or 
derivatives) in their coordination sphere have been exhibiting high potential as 
metallodrugs for cancer treatment.  
 
For new drugs, the evaluation of their binding in the blood to serum proteins is 
mandatory because it influences the bioavailability of the drug and the efficiency 
of its distribution through the body. In addition, HSA binding can improve the 
selectivity of a drug by means of passive targeting to the tumour tissue 21.  
 
The goal of this work was to access the biospeciation in the blood of the complex 
[RuII(η5-C5H5)(bipy)(CO)][PF6] – herein referred to as RuC – by the studying the 
binding of this complex to human serum albumin. In particular, we were 
interested in evaluating the interaction of RuC with HSA under physiological 
conditions, which species may form in the blood and the corresponding binding 
constants involved.  
 
Spectroscopic techniques were used to achieve this goal, namely UV-Visible 
absorption and Fluorescence emission. Given the high sensitivity and versatility 
of the latter, fluorescence was the method chosen to assess the system RuC–HSA 
and to elucidate the complex binding site(s) on HSA using site-markers. 
 
Conclusions gathered from the study executed in this thesis can be used as model 
and are expected to be valid for other compounds with the same type of 
structure and same type of ligands. 
 
The following chapter addresses some details on the techniques used in this 
work, particularly fluorescence spectroscopy. Chapter 4 describes in detail all 
the steps followed to execute the experimental work (reactants, equipment, 
preparation of samples and all the necessary conditions to acquire the results 
obtained in this thesis). Chapter 5 contains results, graphs and tables obtained 
from experimental data for the interaction between RuC and fafHSA, and for the 
systems fafHSA–site marker and RuC. Following this chapter, conclusions and 
future prospects are presented. 
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3.0. TECHNIQUES USED FOR THE STUDY 
 
The interaction of the metal ion complexes and blood serum components can be 
monitored by spectroscopic techniques. These techniques provide useful 
information on the extension and nature of the binding between the metal 
complex and the blood plasma components, particularly with high molecular 
components such as albumin. 
 
The quantitative goal of this work is the determination of the binding constants 
between the protein (HSA) and the complex (RuC). However, before this 
determination could be performed, the stability of the complex in solution had to 
be checked so spectroscopic changes in the samples could be traced as an 
indication of the binding process. In this work, fluorescence and UV-Vis 
spectroscopies were used to characterize the interaction between RuC and 
human serum albumin.  Both techniques provide experimentally simple and 
straightforward methods to evaluate the interaction of biomolecules and metal 
complexes, and in this section some aspects relevant for this work are addressed. 
 
Fluorescence spectroscopy is a highly sensitive technique that has a wide range 
of applications for biochemical and organic substances. It can be used to identify 
compounds and it is increasingly applied in biochemistry. This technique was 
chosen for this work because the serum protein contains natural fluorophores in 
the near ultraviolet region (amino acids that present aromatic side chains, such 
as tyrosine, phenylalanine and tryptophan). Fluorescence emission is more 
sensitive to the environment surrounding the fluorophores than absorption, and 
this is an effective method to detect and follow the binding of ligands, metal 
complexes or structural changes in biomacromolecules 60.  
 
UV-Vis spectroscopy is a very common technique, and the basic principles that 
support it are very well known. As such, this section focuses on the UV-vis 
spectrum of the Ru(II) metal complex being studied. Fluorescence Spectroscopy 
was the technique used for the quantitative approach to the systems studied, and 
for that reason is presented with much more detail. 
 
3.1.0. UV-Vis spectroscopy 
 
UV-Vis absorption spectroscopy was used to assess the stability of the parent 
complex in aqueous solution and to optimize experimental conditions. It is easy 
to agree to the use of this technique for optimization studies due to several 
reasons: it is a method that provides simplicity, results achieved in a rapid 
manner, precision and low cost.  
 
Apart from the n- π* and π- π* transitional bands that can be observed in any 
molecule, some specific bands are identified in the electronic spectra of 
transition metal complexes, such as d-d bands and charge transfer bands. 
 
Charge transfer (CT) bands are often detected in transition metal complexes. 
When the ligand contains a group of orbitals of low energy, there is a possibility 
of a new transition that involves the charge transfer between metal and ligand, 
- 19 - 
 
Metal-to-Ligand Charge Transfer (MLCT) (Figure 11). There is also the possibility 
of transitions between the d-d orbitals from the metal and the orbitals from the 
ligands. These charge transitions between the metal and ligand derive into 
absorption bands in the visible, whereas the transitions in the ultraviolet come 
from the transitions within the ligand orbitals, which are normally n- π* and π- 
π* 61. 
 
The compound studied in this work is a ruthenium(II)-cyclopentadienyl complex 
with a piano-stool structure. In this structure, quite different from the octahedral 
or tetrahedral geometries typically found in metal complexes, the 
cyclopentadienyl ligand is considered as the seat of the stool, and the three 
remaining coordinating positions are considered the three legs. The crystal 
structure of the complex [Ru(Cp)(bipy)(PPh3)]+ (also known as TM34) is 
reported in the literature; this complex is very similar to RuC, with a 
triphenylphosphine co-ligand (PPh3, Ph or C6H6 is a phenyl substituent) 
replacing the CO ligand 21. 
 
Figure 11. Scheme to elucidate the possibility of charge transfer bands in a tetrahedral geometry 
for a low spin Ru(II) complex where the two orbitals d of lower energy are complete with four 
electrons. According to the Cristal Field Theory (CFT), t2g orbitals comprise three d orbitals 
dxy,dxz,dyz and eg refer to the d orbitals dx2-y2 and dz2; the relative energy of the two sets of d 
orbitals is strongly dependent on the metal complex structure (octahedral or tetrahedral). (∆, 
energy difference between eg and t2g, MLCT, metal-to-ligand charge transfer) (modified from 
ref60). 
 
The UV-vis absorption spectrum of RuC in pH 7,4 HEPES buffered medium is 
shown on Figure 12. 
 
                            Figure 12. UV-VIS absorption spectrum for RuC, (in 10 mM HEPES pH 7,4) 
The intense bands in the UV range (250 nm-320 nm) are assigned to π- π* 
electronic transitions occurring in the coordinated aromatic rings. In the range 
320-380 nm the bands are assigned to electronic transtions occurring in the 
organometallic moiety [Ru(Cp)(bipy)]+ and in the coordinated bipy 
chromophore, as was observed for the complex  TM34 where the 
triphenylphosphine ligand replaced the CO 21, 26. 
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In the visible region (380-500 nm) several undefined bands can be assigned to 
metal-to-ligand charge transfer bands (MLCT) from the Ru 4d orbitals to π* 
orbitals of the bipy N-heteroaromatic ring 21, 25. 
3.2.0. Fluorescence spectroscopy 
 
Luminescence is described as the light emitted from any substance which occurs 
from electronically excited states. Depending on the nature of the excited state, 
luminescence is divided into two categories: phosphorescence (involving excited 
triplet states) and fluorescence (relating to excited singlet states) 60, 62.  
 
Two processes are thus included in fluorescence spectroscopy, the absorption of 
light from a beam of electromagnetic radiation (promoting an electron to an 
excited state) and the emission of light by a chemical compound (the 
fluorophore).  
 
After a fluorophore is excited to a higher vibrational level (S1 or S2), molecules in 
condensed phases (with few exceptions) rapidly relax to the lowest vibrational 
level of S1.  This process is called internal conversion and occurs rapidly, within 
10-12 s or less. The return to the ground state (S0) can be accompanied by 
luminescence or by other non-radiative decay (internal conversion or 
intersystem crossing, to name a few). These processes are typically depicted in a 
Jablonski diagram (Figure 13) and the light energy emitted is always of longer 
wavelengths 60. 
 
Figure 13. Displays one form of a Jablonski diagram where the luminescence phenomena are 
represented (ref60). 
 
The fluorescence quantum yield (ɸF) is defined as the ratio of the number of 
photons emitted to the number absorbed and depends on the emissive rate of 
the fluorophore (Γ) and on the non-radiative decay to S0 (knr), which depopulate 
the excited state. One of the approaches to obtain the fluorescence quantum 
yield is as follows (Equation 1): 
         ɸF 
 
     
                    Equation 1 
 
The different fluorescence measurements performed in this thesis are described 
in the next subsections. 
 
 
 
 
- 21 - 
 
3.2.1. Steady-state measurements: emission spectra. 
 
If there is only one species in the fundamental state, the excitation spectrum is 
identical to the absorption spectrum (i.e. the two spectra overlap). However, if 
more than one species is present or only one species but in different ionization 
states, the spectra do not overlap.  
 
Considering all emitted photons, whatever their energy in order to express the 
steady-state fluorescence intensity per absorbed photon as a function of the 
wavelength of the emitted photons F(F) and satisfying the relationship 
(equation 2), where ɸF is fluorescence quantum yield defined above.  
 
       ∫   (  )      
 
 
              Equation 2 
 
F(F) symbolizes the fluorescence spectrum or emission spectrum, reflecting 
the distribution of probability of several transitions from the lowest vibrational 
level (S1) to the various vibrational levels of S0.  The emission spectrum is 
characteristic of a given compound 62.  
                                                      
The steady-state fluorescence intensity IF (F) measured at wavelength F 
(chosen by a monochromator with a certain wavelength bandpass ∆F) is 
proportional to F (F) and to the number of photons absorbed at the excitation 
wavelength E (selected by a monochromator) 62.  
 
The Stokes shift is the gap between the maximum of the first absorption band 
and the maximum of the fluorescence emission spectrum and it is most dramatic 
for polar fluorophores in polar solvents, due to interactions between the 
fluorophore and its immediate environment. This important parameter provides 
information on the excited states. For example, when the dipole moment of a 
fluorescent molecule is greater in the excited state than in the ground state, the 
Stokes shift increases with solvent polarity, which means emissions with lower 
energy or longer wavelengths (red shift). These shifts are very useful in 
fluorescence spectroscopy in order to predict the polarity of the area where the 
fluorophore is located 60, 62.  
 
3.2.2. Fluorescence quenching mechanisms 
 
Fluorescence quenching is the process that decreases the fluorescence intensity 
of any sample. There are a variety of molecular interactions that could result in 
quenching, including: molecular rearrangements, energy transfer, ground-state 
complex formation, excited-state reactions and collisional quenching. 
 
In systems where more than one species is present, fluorescence emission 
intensity can be diminished by a process of self-absorption/Inner filter effect 
exerted by one of the components. Inner filter effect is the phenomenon arising 
when the recorded fluorescence intensity is not proportional to the 
concentration of the fluorophore due to the absorption of a fraction of the 
incident light before it reaches the point in the sample at which luminescence is 
observed, and re-absorption of some of the emitted light before it leaves the cell. 
- 22 - 
 
As a consequence, the observed fluorescence intensity depends on the optical 
density of the sample at both excitation and emission wavelengths 63. These 
effects are quite important when a species absorbs light in the wavelength range 
where the emission of the fluorophore is collected. In other words, these effects 
are undoubtedly observed when the emission spectrum of the fluorophore 
overlaps with the absorption spectrum of other species that coexist in solution. 
This results in a “quenching effect” that does not indicate any interaction. 
Nevertheless the effect can be corrected using Equation 3: 
 
                                                                    
(       )                   Equation 3  
 
Where IFcorrected and IFmeasured are the corrected and measured fluorescence 
intensities, and Aex and Aem are the absorptivities at the excitation and emission 
wavelengths in the samples, respectively 60. The inner filter effect was performed 
for the range of all the absorbances of the spectra obtained. 
 
There are two types of quenching: static and dynamic. Static and dynamic 
quenching needs molecular contact between the quencher and fluorophore in 
order to successfully quench the intensity. However, there is also the possibility 
of a dual mechanism when both occur at the same time. 
 
In the case of collisional or dynamic quenching, the quencher must spread to the 
fluorophore during the lifetime of the excited state and after the contact, the 
fluorophore returns to the ground state without emitting a photon. This 
mechanism happens without any enduring change in the molecules (without a 
photochemical reaction).  
 
Collisional quenching can be described by the Stern-Volmer equation:  
 
        
   
  
  1 + kqCq = 1 + KD Cq                          Equation 4 
 
In this equation IF0 and IF are the fluorescence intensities in the absence and 
presence of quencher, respectively; kq is the bimolecular quenching constant; 
is the lifetime of the fluorophore in the absence of quencher, KD is the Stern-
Volmer quenching constant and Cq is the concentration of quencher. 
 
The Stern-Volmer quenching constant indicates the sensitivity of the fluorophore 
to a quencher: for a fluorophore buried in a macromolecule and inaccessible to 
water-soluble quenchers the value of K is low, and larger values are observed for 
a fluorophore that is on the surface of a biomolecule. 
 
Fluorescence quenching can also occur by other processes. In static quenching 
the ligand is bound to the protein and the fluorescent intensity decreases with an 
increasing concentration of protein-ligand complexes. The result of the 
quenching is due to the formation of a non-fluorescent ground-state complex 
between the fluorophore and the quencher. The equilibrium between a 
fluorophore plus a quencher and the fluorophore-quencher complex is given in 
Equation 5. 
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                   F + nQ     FQn                   Equation 5 
                                                       
In this equation F is the free fluorophore, n is the number of quenching 
molecules that bind to the fluorophore, Q is the free quencher, k1 is the 
association rate, k-1 is the dissociation rate and FQn is the fluorophore-quencher 
complex. The association constant Ks can be calculated with the following 
equation (Equation 6). 
      
     
       
 
  
   
                                Equation 6
                                                                                      
The total concentration can be calculated with the following equations (the start 
concentrations of protein and ligand are given by [F]0 and Cq0, respectively) 
                                                             
                            Equation 7 
             
                                                                                  Equation 8 
                                                      
After substituting equation 8 into equation 7 and some other arrangements with 
equation 6, the following equation is obtained: 
 
         
   
  
=  
    
   
        
   Equation 9 
 
where Ks is the association constant and [Q] or Cq the concentration of the 
unbound fraction of the quencher. 
 
A linear Stern-Volmer plot is generally an indication of the presence of a single 
class of fluorophores, all equally accessible to the quencher. If two fluorophore 
populations are present and one is not accessible to the quencher, or if the 
number of acting quencher molecules is more than one, the Stern-Volmer plots 
deviate from linearity towards the x-axis.  
 
In many occasions the fluorophore can be quenched by both collisions and by 
complex formation with the same quencher. The characteristic feature displayed 
on the Stern-Volmer plots in these circumstances is an upward curvature 
concave towards the y-axis (see Figure 15  in 3.2.3).  
 
As a result, the Stern-Volmer equation is modified and second order in Cq, which 
accounts for the upward curvature observed (Equation 10). 
 
                  
   
  
 (      )(      )    (     )         
  Equation 10 
                                                             
The dynamic portion of the observed quenching can be resolved with lifetime 
measurements (see next section).   
 
Quenching measurements can reveal the accessibility of quenchers to 
fluorophores because if the protein was impermeable to the quencher and the 
fluorophore was situated inside the macromolecule, neither static nor dynamic 
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quenching would occur. Therefore, quenching studies are utilised to 
acknowledge the position of fluorophores in membranes and proteins 60. 
 
Steady-state fluorescence is a very common method to study protein-ligand 
interactions. (In this context, “Ligand” can be an organic molecule or a metal 
complex that interacts with the protein and binds to it). In proteins, the three 
aromatic amino acids – phenylalanine, tyrosine, and tryptophan – are all intrinsic 
fluorophores, the dominant fluorophore being the indole group of tryptophan. 
 
The emission spectra of tryptophan often changes in response to denaturation, 
conformational transitions, subunit association or substrate binding. Tryptophan 
seems to be only sensitive to collisional quenching, due to a tendency of excited-
state indole to donate electrons, and can be quenched by nearby groups within 
the protein or by externally added quenchers. 
 
In fluorescence, proteins are normally excited at 280 nm or longer wavelengths. 
The absorption of proteins at this wavelength is due to tyrosine and tryptophan 
residues, but when the protein is excited at longer wavelengths than 295 nm, the 
absorption is mainly due to tryptophan 60.  
 
Human serum albumin (HSA) exhibits 18 Tyrosine residues and one lone 
Tryptophan, Trp214 (see section 1.3.2.). Thus Trp214 can be used as a 
structural probe in the protein, using 295 nm as the excitation wavelength, and 
this very attractive feature combined with the high sensitivity of the 
Fluorescence spectroscopy makes it a preferred method for studying the binding 
of small molecules to HSA. 
 
3.2.3. Time-resolved measurements  
  
In time-resolved Fluorescence it is the intensity decay of the fluorescent sample 
that is measured: the sample is exposed to a pulse of light (such as a LED source), 
and the emission intensity decay is recorded with a high-speed detection system 
on the nano-second timescale 60. 
 
The relationship between steady-state and time-resolved measurements can be 
understood using Equation 11. The steady-state intensity (Iss) is related to the 
decay time by  
 
        ∫   
 
 
    ⁄                     Equation 11 
 
I0 can be considered a parameter that depends on the fluorophore concentration 
and on several instrumental parameters. A steady-state measurement is simply 
an average of the time-resolved phenomena over the intensity decay of the 
sample. 
 
There are two methods to measure time-resolved fluorescence: frequency-
domain and time-domain. Time-domain is the method used in this thesis and it is 
described below. 
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In the frequency domain or phase-modulation method, the sample is excited 
with intensity-modulated light. The intensity of the incident light is varied at a 
high frequency typically around 100 MHz, therefore, its reciprocal frequency is 
comparable to the reciprocal of decay time . When a fluorescent sample is 
excited according to this method, the emission is forced to respond at the same 
modulation frequency. The lifetime of the fluorophore causes the emission to be 
delayed in time relative to the excitation, represented as a shift 60.  
 
In the time domain or also called pulse fluorometry method, a pulse of light 
excites the sample, this is the most popular technique to determine lifetime 
measurements. The width of light is made as short as possible and it is by 
preference much shorter than the sample´s decay time . In order to register the 
time-dependent intensity the excitation pulse is followed, the decay time  is 
then calculated from the slope obtained by plotting log I(t) versus t or from the 
time at which the intensity decreases to l/e of the intensity at t=0 60. 
 
Most instruments are based on the time-correlated single-photon counting 
(TCSPC) method or also called single-photon timing (SPT). The main principles 
depend on the fact that the likelihood of detecting a single photon at a certain 
time t after an exciting pulse is proportional to the fluorescence intensity at that 
time. Recording a single photon involves the timing between the excitation pulse 
and its emission, the distribution of collected data recorded over time is 
represented in the form of a histogram 62. 
 
In this work, the excitation pulse is generated by a nanoLED (pulse light-emitting 
diodes that emits pulses of light with an ideally regular and infinitesimal 
duration) which is routed through a discriminator (CFD, constant function 
discriminator), the corresponding electrical pulse is forwarded to the start input 
of the time-to-amplitude converter (TAC) that generates a ramped voltage that 
increases gradually with time. Meantime, the sample is excited by the pulse and 
emits fluorescence. The optics is adjusted so the photomultiplier does not detect 
more than one photon per exciting pulse. The corresponding electrical pulse is 
routed through a discriminator to stop the input of the TAC and then this 
generates a voltage directly proportional to the delay time between excitation of 
the pulse and the photon detection (∆t) 62.  
 
The analysis of this pulse is achieved by an analogue-to-digital converter (ADC) 
that converts the voltage into a digital value and a multichannel analyser (MCA) 
then adapts the numerical information, developing a histogram from the sum of 
several pulses (countagens versus time, Figure 14) 60, 62. 
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Figure 14. Example of an histogram of a fluorescence species along with the time (modified from 
ref60) 
 
Fluorescence intensity decays are achieved after a very short pulse of light with 
sufficient energy has brought a specific number of molecules to an excited state. 
Because of the fact that the rate constants for the radiative and non-radiative 
procedures (kr and knr) are first order, the fluorescence intensity i(t) observed at 
a time t after excitation by a very short pulse of  light at time 0, is proportional to 
the instantaneous concentration of molecules still excited [A*], and it is given by 
the following equation 62: 
           i(t)= kr [A*]0 exp (-t/0)           Equation 12 
 
where kr is the radiative rate constant, [A*]0 is the number of excited molecules 
per volume unit, t is the time and 0 is the lifetime of the excited state (which is at 
the same time 0=1/(kr+knr)). The intensity decreases with time according to an 
exponential law and the fluorescence decays can be described by a single 
exponential (simple decay) or by a sum of them (complex decays). The following 
equation describes a multi-exponential decay with n components, intensity 
decays are typically fit to this model 60, 62:  
 
              i(t)= ∑      i exp (-t/i)           Equation 13 
 
where αi is a pre-exponential factor which is related to fi (fractional contribution 
of each chromophore species to the total fluorescence intensity) and i is the 
lifetime of the i species. Therefore, according to this equation, after the pulse 
excites the molecules, the fluorescence intensity decreases exponentially along 
with time 62. 
 
The natural way of describing an average decay time (or lifetime) when the 
fluorescence decay of a fluorophore is multi-exponential is 62:  
 
           〈 〉  
∑     
  
   
∑     
 
   
 ∑     
 
                          Equation 14 
                                              
Each decay time is weighted by the corresponding fractional intensity. The 
average is called the intensity-averaged decay time (or lifetime). This 
corresponds to the lifetime of the excited state that is defined as the average time 
that a molecule spends in the excited state before returning to the fundamental 
state 60, 62. 
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Another possibility is to use the amplitudes or pre-exponential factors as 
weights: 
               ̅  
∑     
 
   
∑   
 
   
 ∑     
 
              Equation 15 
                                                      
where αi are the fractional amplitudes 
 
                                                  
  
∑   
 
   
    being   ∑     
 
    
                                       
The weighted amplitude-average lifetime is proportional to the quantum yield 
and therefore it is also called weighted lifetime for quantum yield 62. 
 
This type of measurement provides information not available from the steady-
state data: to distinguish static from dynamic quenching processes lifetime 
measurements are essential 60. In fact, the dynamic portion of the observed 
quenching can be in a mixed static and dynamic quenching process can be 
determined by lifetime measurements using: 
 
0/ = 1 + KD Cq.           Equation 16 
 
which accounts for the linear dashed line (with slope KD) in Figure 15. 
 
 
Figure 15. Stern-Volmer plot of a dual mechanism dynamic and static quenching of the same 
population of fluorophores 60. 
 
3.3.0.  PSEQUAD 
 
PSEQUAD is the program used in this work for the estimation of binding 
constants. In a quantitative approach to any binding process, the major goal is to 
calculate the binding constant(s) involved in the system and the stoichiometry of 
the bound species formed. 
 
The equilibrium process can be described by  
 
p (ligand) + q (HSA) {(ligand)p(HSA)q} 
 
and the global conditional binding constant pq’ in a buffered medium is defined 
by 
         
 (      ) (   )  
               
              Equation 17 
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In this notation “ligand” refers to any small molecule binding to the protein 
(HSA). In the specific case of the work involved in this thesis, “ligand” is in fact 
either RuC or a site-marker. 
 
The computer program PSEQUAD evaluates spectroscopic and/or 
potentiometric equilibrium data using analytical derivatives 64. The equilibrium 
system can be defined by the following mass-balance equations such as: 
 
                        ∑    [  ]
 
    ∑    
 
     ∏     
    
    (     )       Equation 18 
                        
where Ct is the total concentration of the tth component, n corresponds to the 
number of species present in the system (including the components), Sj is the jth 
species present in the system, k is the number of components in the system, [ci] 
is the equilibrium concentration of the ith component, βj is the global formation 
constant of the jth species, and αji the stoichiometric numbers, giving the number 
of the ith component in the jth species, α is called composition matrix. 
 
In order to solve this equation, PSEQUAD calculates the unknown free 
concentrations based on the standard Newton-Raphson procedure and obtains 
the unknown formation constants and/or molar absorbances by minimizing the 
F function by an iterative cyclic procedure.  
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          Equation 19 
                    
where wl is the weighting factor of the titrant´s volume or total concentrations, 
wl is the weighting factor for the lth potential measurements, wA is the weighting 
factor for the absorbance measurements and Fq is any function correctly 
composed from the experimental data 64. As a result, what is is minimized in the 
calculations is: 
 wA ∑(∆Aexperimental-∆Acalculated)2           Equation 20 
 
where ∆Acalculated is achieved for each wavelength, from the reagents´ 
concentrations used, log β values in use and ∆ε values in use for each emitting 
component. The meaning of “in use” is that the values are being used for a 
determined iteration and changing between iterations until the minimization of 
the function is accomplished. 
 
Steady-state fluorescence results were used to calculate binding constants for 
adducts formed using PSEQUAD. In these calculations, RuC is simply referred to 
as C for clarity; so, and adduct formed between albumin and RuC with a 1:1 
stoichiometry is {HSA-C}, one with a 1:2 stoichiometry is {HSA-C2}. The systems 
analysed also included {HSA-site marker} and {HSa-site marker-RuIIcomplex} 
adducts. For the systems evaluated in this work, the mass-balance equations can 
be written as 64:  
                                           ∑   
 
      
                           Equation 21 
 
           ∑      
                                Equation 22 
where, 
 β’pq= overall conditional binding constant of HSA- “ligand” complexes 
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 cx= analytical (total) concentration of component x (HSA or “ligand”) 
 [x]= equilibrium concentration of component x 
 Q= 1 (typically for the albumin system) 
whereas, 
Ii=Φiligand x [ligand]+ΦiHSA x [HSA]+ΦiHSA-ligand x [HSA-ligand]   Equation 23 
with 
 Ii=fluorescence emission intensity at “I” nm (at each wavelength i) 
Φix=proportional constant for component x at “I” nm (between Ii and 
equilibrium concentration of x); “molar intensity” 
 
It is important that strictly identical parameters of the instrument are used at 
each measuring set for results evaluated in the same input file for PSEQUAD. 
The program provides the standard deviation of the stability constant(s) 
calculated. The quality of the calculations achieved with PSEQUAD is reported by 
the program in the form of a fitting parameter, FP (which includes the error 
square sum), that represents how good the fit between the measured and 
calculated values is. 
 
In the case of the fluorimetric titrations, the measured and calculated emission 
spectra are compared, and PSEQUAD calculates values of β’pq with iterative 
cycles (Newton-Raphson procedure) by fitting these spectral data till the 
minimum difference between the data is reached. For fluorescence data, an FP in 
the range of 2x105-3x105 represents ca. 1-2,5% deviation between the measured 
and calculated values at the emission maximum. 
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4.0. EXPERIMENTAL PART 
 
4.1.0.  Reagents 
 
Commercially available chemical reagents and albumin were used as delivered 
from the supplier without any further purification. 
 
Human Serum Albumin fatty acid free (fafHSA or simply HSA) (A3782) was 
provided by Sigma-Aldrich, lyophilized powder with a molecular mass of ca. 
67000 g/mol. Warfarin (WF) (A2250) and Dansylglycine (DG) (D0875) 
(lyophilized powder) were purchased from Sigma-Aldrich and used without any 
further purification.  
 
The ruthenium(II) complex studied in this thesis was [RuIICp(bipy)(CO)][PF6] 
which was synthesised and provided by Dr. Andreia M. Valente from the Quimica 
Organometálica e Biorganometálica group, Faculdade de Ciências, Universidade 
de Lisboa. 
 
4.2.0. Preparation of solutions 
 
Water: Millipore® water from a Millipore Milli-Q water purification system was 
used to prepare all aqueous solutions. 
  
Buffer: 4-(2-hydroxyethyl)-1-piperazineethane Sulfonic acid (HEPES) was 
prepared and then used to make the samples. In order to prepare this buffer, 
typically 1.19 g of HEPES provided by Sigma-Aldrich were weighted, transferred 
into a 500 mL volumetric flask and then filled up with Milli-Q water yielding a 
final concentration of 10mM. Concerning the pH adjustment, concentrated 
solutions of HCl 2 M and KOH 4 M provided by VWR, were required to achieve a 
final pH of 7,4. 
 
Ruthenium complex (RuC) solutions: the preparation of stock solutions and 
following dilutions was required in order to achieve more accurate pipetting. To 
prepare the ruthenium solutions for the experiments with the ruthenium 
complex, typically 1 mg of the complex was weighted into a 10 mL volumetric 
flask and dissolved in HEPES 10 mM, pH 7,4, yielding a typical concentration of 
1,9-3,6x10-4 M. The solutions were freshly prepared for each experiment 
immediately before use. 
 
Albumin solutions: Albumin solutions were freshly prepared for every 
experiment by dissolving fafHSA in 10 mM HEPES. Albumin stock solutions were 
allowed to stand for at least 30 minutes at room temperature to allow the 
protein to hydrate and fully dissolve, being gently swirled from time to time. The 
concentration of each fafHSA solution was determined spectrophotometrically by 
UV-vis absorption using a molar extinction coefficient of 278 nm =36850 M-1 cm-1 
65, 66. 
 
HSA-RuC samples: These samples were prepared varying conditions such as 
concentration of the protein and incubation time to optimize measurement 
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conditions and equipment parameters (eg. bandwidth for the excitation and 
emission of the fluorescence intensity). Individual protein-complex samples 
were prepared to ensure in each assay the same incubation time at (37,0 ± 0,5) 
ºC. All samples were prepared with a total volume of 4 mL in glass vials. The 
specific volumes of protein and complex solutions were added to each glass vial 
according the concentration required and then filled up with HEPES to a total 
volume of 4 mL. Samples were then inserted into the oven and allowed to 
incubate for (24 ± 1) h. 
 
Samples of the experiments incubated and measured at (37 ± 1) ºC had a final 
protein concentration that varied from 2,0 µM to 5,2 µM (kept constant), and the 
complex concentration was varied accordingly to obtain HSA:RuC molar ratios 
ranging from 1:0,5 to 1:24. 
 
Samples with the same complex concentration but with no protein were 
prepared for appropriate background correction. 
 
Warfarin (WF) stock solutions: Warfarin stock solutions of approximately 100 
µM was prepared and used within a week (maximum). The stock solution 
concentration was determined on the basis of the UV-vis spectrum using 308 
nm=14475 M-1 cm-1, Molecular weight (MW) = 308,34 g/mol 57. 
 
Warfarin samples: In order to prepare these samples, adequate dilutions from 
the stock solution were executed to obtain a final concentration in these samples 
that varied from 5 to 80 µM. The final volume of these samples was 4 mL. 
 
Warfarin-HSA-samples: These samples were prepared with a final volume of 
4mL in HEPES medium, keeping the concentration of HSA constant at 2 µM and 
varying the concentration of WF from 0 to 40 µM. Samples were incubated at 37 
ºC for at least one hour before measuring the fluorescence. A sample of HSA 
alone was prepared simultaneously with the other samples and measured for 
background corrections. 
 
WF-HSA-RuC samples: These solutions were prepared in HEPES medium 
keeping the concentrations of HSA and WF constant at 2 µM (equimolar) and 
varying the concentration of RuC from 0 to 44 µM, for a final volume of 4 mL. 
Before adding the complex to the samples, the adduct {HSA-WF} was incubated 
at 37 ºC for one hour, after which an adequate volume of RuC stock solution was 
added to each sample. These were then incubated for 24 hours in the oven at 37 
ºC. A sample containing complex alone was prepared simultaneously with the 
other samples and measured for background corrections. 
 
Dansylglycine (DG) stock solutions: Dansylglycine stock solutions were 
prepared following the same procedure as for Warfarin and the final 
concentration was assessed by UV-Visible spectroscopy using a molar extinction 
coefficient of 327 nm= 5068 M-1 cm-1, MW= 308,4 g/mol 57. 
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Dansylglycine samples: In order to prepare these samples, simple dilutions 
from the stock solution were performed. The concentrations of these samples 
varied from 1 to 40 µM. 
 
Dansylglycine-HSA and Dansylglycine-HSA-RuC samples: These samples 
were prepared from the dansylglycine stock solutions following the same 
procedure as for WF-HSA and WF-HSA-RuC solutions. 
 
A comprehensive list of the essays performed with detailed information is 
included in Annex A1, table 1. 
 
4.3.0. Equipment 
 
The pH of samples and buffer solutions was adjusted with a VWR international 
1000 pH meter in order to monitor the pH changes equipped with a LE409 
combined glass electrode from Mettler Toledo. 
 
To keep the samples at the required temperature a Stuart scientific block heater 
SBH200D/3 (Staffordshire, United Kingdom) was used. This thermoblock device 
was used when the required temperatures were room temperature or higher. 
For low temperature measurements, incubations executed in a LAUDA Ecoline 
star edition bath. 
 
Balance: All reactants were weighted in a AX205 balance from Mettler Toledo 
with a 0,01 mg sensitivity. 
 
Micro pipettes were from Eppendorf (2-20 µL (±1,0% accuracy), 20-200 µL 
(±1,0-5,0% accuracy), 100-1000 µL (±0,6-3,0% accuracy) or VWR International 
(20-200 µL (±2,5-0,5%), 100-1000 µL (±0,9-0,6%), 1-5 mL (±0,6-0,5%)). 
 
Cell holder bath: temperature control in the sample compartment of the 
spectrofluorometer was set by a Thermomix BU B. Braun thermobath equipped 
with a Frigomix U B. Braun as the cryostat controller. 
 
Quartz cells: Suprasil quartz cells used 1 cm x 1 cm and 1 cm x 0,4 cm were from 
Hellma Analytics (Müllheim, Germany). The cells with the 0,4 cm optical path 
were used for absorbance and fluorescence measurements and the ones with 1 
cm optical path only for the stability studies in the spectrophotometer (volume 
of the cells 1,4 mL) 
 
An INCU-Line® incubator model IL53 from VWR international was used to 
incubate all samples (±0,5 ºC). 
 
UV-Vis spectrophotometers: A JASCO V-660 spectrophotometer was used to 
perform all stability studies. Another spectrophotometer JASCO V-560 was used 
while performing the steady-state measurements. UV-vis absorption spectra 
were recorded at room temperature in the range 250-600 nm with 0,4 and 1 cm 
path Hellma® Analytics quartz suprasil cuvettes. Spectra for the experiments 
involving warfarin and dansylglycine were also recorded at room temperature in 
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the range 250-600 nm with the same cuvettes. A scan rate of 400 nm/min was 
typically used. 
 
Spectrofluorimeter: Fluorescence measurements were performed in a 
Fluorolog-3 v2.2 Jobin Yvon HORIBA. Emission spectra were recorded in the 
range of 310-550 nm for HSA-RuC samples with excitation=295 nm, in the range of 
320-590 nm withexcitation=310 nm for the experiments involving warfarin and in 
the range of 345-620 nm with excitation=335 nm for the experiments involving 
dansylglycine, using a 0,2 s integration time. Fluorescence emission intensity 
was corrected for the absorption and emission inner filter effects 60, 67 using the 
UV-Vis absorption data recorded for each sample (Equation 3, see section 3.2.2). 
 
Time-resolved measurements were performed in a Fluorohub v2.0 also from 
HORIBA Jobin Yvon that was connected to the spectrofluorometer with a time 
scale of 55517 ps/channel. The maximum number of counts was 10000. The 
nanoLED light source used (279 nm) for the lifetime measurements was from 
HORIBA Jobin Yvon. Ludox® was used as the scatterer to obtain the instrumental 
response function and was provided by Sigma-Aldrich. 
 
Suprasil quartz cells 1 cm x 0,4 cm used for steady-state and time-resolved 
fluorescence measurements were positioned with the largest optical path 
towards the excitation direction. Consequently, the excitation was performed 
along the 1 cm face of the cell and the emission collected from the 0,4 cm face. 
This procedure allowed to increase the intensity of the signal received. 
 
In each assay blank specimens (samples that do not contain the fluorophore) 
were included, which were subtracted from the intensity for each sample. The 
entire procedure was executed for all the samples in the same manner, with the 
adequate excitation wavelength and slits. In order to be able to compare the 
experiences, these parameters need to be similar for the same type of sample, 
and they are listed in Table 1.  
 
Table 1. Bandwidth or slits (nm) used in spectra recorded from the different experiments 
performed (emission spectra and lifetime measurements) and the nanoLED source used for each 
experiment.  
Name of samples Emission spectra 
(slits, nm) 
Lifetime measurements 
(nanoLED bandwitdth) 
HSA-RuC (37ºC): 
HSA(2.25µM) 
HSA(2.5µM)* 
HSA(2µM) 
 
2 
2 
2 
(279 nm nanoLED) 
15 
10, 13 and 14 
15 
HSA(2µM) 4 (279 nm nanoLED) 
15 
Warfarin experiments (37ºC) 
WF alone samples 
WF-HSA samples 
WF-HSA-RuC samples 
 
2 and 3 
2 and 2.5 
2 and 3 
 
NA 
Dansylglycine experiments (37ºC) 
DG alone samples 
DG-HSA samples 
DG-HSA-RuC samples 
 
2 and 4 
2 and 2.5 
2 and 3 
 
NA 
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4.4.0. Spectroscopic measurements: other experimental details 
 
Emission spectra can be distorted by variations in the intensity of the excitation 
light, being these variations due to the dependence of the wavelength on the 
intensity of the lamp and the efficiency of transmission of the emission 
monochromator and for the detector response (photomultiplier tube). Because 
of this, a correction for the acquired spectra is needed, mainly for quantitative 
measurements 62. The variations in the intensity of light were eliminated by the 
division of a reference signal while the remaining distortions were removed by 
applying a correction to the measured raw signal using correction files provided 
by the manufacturer. 
 
For time-resolved fluorescence measurements the Fluorohub v2.0 coupled to the 
spectrofluorimeter (used for the steady-state measurements) was used. This 
allowed to measure fluorescence decays with the Single Photon Timing (SPT) 
technique. In this case, the excitation was performed by a pulsed nanoLED and 
for the detection a photomultiplier tube TBX-04 with a resolution of 50 ps was 
used. 
 
The nanoLED used was chosen according to its wavelength. This wavelength had 
to be as close as possible to the excitation wavelength required of the sample in 
question and the emission collected, to the wavelength of maximum emission. 
For these measurements it was only necessary to control the emission slits since 
the radiation emitted from the nanoLED is essentially monochromatic (Table 1). 
During these experiments, the signal was recorded at emission wavelengths 
chosen according to the results from the steady-state measurements. 
 
In the time-dependence studies, the time needed for the binding of RuC to HSA to 
reach thermodynamic equilibrium conditions was evaluated. Measurements 
were performed for the same samples (protein in the presence and in the 
absence of the complex, and also complex alone) every certain period of time, 
and one sample of each type was prepared for the whole session (three samples 
in total). A concentration of 4 µM was chosen for the protein samples and 40 µM 
for the complex. These three samples were measured at 37 ºC in the 
spectrofluorometer and straight after in the UV-Vis at room temperature ~25 ºC. 
For these studies the 1 cm x 0,4 cm quartz cells were used. 
 
4.5.0. Data processing 
 
The change in the UV-Visible absorption spectra was evaluated in: i) the solution 
stability study for RuC, and ii) in the time-dependence study of the interaction of 
RuC and the protein. These measurements were executed in 10 mM HEPES pH 
7,4. The change in the different spectra recorded was assessed at a specified 
wavelength value with Equation 24. 
 
                                              % Variation =|
(         
    
|                            Equation 24 
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Where Absi is the absorbance at time i and Abs0 the absorbance at the initial time 
(time zero). 
 
-Time-resolved fluorescence decays 
 
Data processing for results from the lifetime measurements was done using the 
program Time-resolved fluorescence Anisotropy (TRFA) version 1,3 (Minsk, 
Belarus). The quality of the adjustment was assessed by a reduced χ2 value that 
was not higher than 1,8 and a random distribution of weighted residuals and 
residuals autocorrelation. 
 
Each fluorescence decay was evaluated fitting a sum of one, two or three 
exponentials and then values of χ2 were compared in order to identify the best 
fit. The value of χ2 is calculated by TRFA from Equation 25 using the observed 
experimental fluorescence decay (R(t)) and the final response function (F(t)) by 
a least squares analysis method that calculates the expected value of R(t) given, 
considering values of αi and  i. The calculated value [Rc(t)] is then compared to 
the observed one R(t). The αi and  i values are altered until achieving the best fit. 
The goodness of the fit is calculated with  
 
                                                       χ2 ∑    ( )    ( ) 
  
   
          Equation 25 
 
where w=1/R(t) is a statistical weighting factor to account for the expected error 
for each value of R(t). 
 
Values of χ2 between 1 and 1,2-1,3 indicate an excellent fit. In what concerns the 
autocorrelation or plot of residuals, a random distribution around zero indicates 
the best fit. 
 
In the present work, the decay recorded in some cases was slightly affected by 
the quality of the connection of the fibre optic cable, which resulted in lesser 
quality data and some χ2 values higher than 1,8.  
 
4.5.1. Static and Dynamic quenching constants 
 
The calculation of the static and dynamic quenching constants (Ks and KD) was 
done by a regression with variance analysis (ANOVA), fitting either a straight 
line or a second order polynomial to the experimental points. Using Equations 
10 and 16 from sections 3.2.2. and 3.2.3., respectively, a linear fit to the 
fluorescence lifetime  0/   plot yielded KD, and KS was then calculated from the 
parameters adjusted by the quadratic fit to IF0/IF. A confidence level of 95% was 
used in all fits and the value of R2 obtained is indicated in all cases.  
 
PSEQUAD – Global conditional binding constants 
 
The emission spectra obtained from the steady-state measurements were used 
to create input files for the determination of the conditional binding constants 
with the computer program PSEQUAD 64. In the input file, the total 
concentrations of each of the components of the system (RuC, protein, site-
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marker) is required and the program reports the best values for the global 
conditional binding constants (calculated as Log β’pq values) from the data used 
in each input file. The quality of the fit is evaluated by FP, the fitting parameter- 
please see Annex C (for more details on FP and PSEQUAD). 
 
Speciation diagrams 
 
The program HYSS (Hyperquad Symulation and Speciation- version 4.0.31) was 
used in this thesis to obtain speciation diagrams for the systems being studied. 
The program uses the binding constants values obtained with PSEQUAD to plot 
the equilibrium concentration of each species present in the system according to 
the total concentration of the protein and RuC complex given (e.g. in the 
conditions used for the measurements). Speciation diagrams presented in this 
work were drawn using 101 points. 
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5.0. RESULTS AND DISCUSSION 
 
All results presented in this chapter are expressed as (value ± SD): the results from 
the Stern-Volmer studies were obtained with variance analysis (ANOVA) 
regression fit, with the least squares method. The standard error associated to the 
value is presented as Standard deviation, with a 95% level of confidence).  
 
Results of conditional binding constants obtained with the program PSEQUAD are 
presented with a fitting parameter (which includes the error square sum), that 
represents how good the fit between the measured and calculated values is. 
 
5.1.0. Stability of the studied complex (RuC). 
 
The stability of the Ru(II) complex [RuII(η5-C5H5)(bipy)(CO)][PF6] (RuC) in the 
medium that will be used to study its interaction with HSA has to be checked. In 
addition, it is necessary to choose the best incubation time in order to achieve 
consistent results on the following experiments. In this study two different 
aqueous media were used: water and an aqueous medium buffered with 10 mM 
HEPES pH 7,4. This stability test was performed at room temperature and in 
absence of light. 
 
 Water 
 
Figure 16 shows the change observed on the UV-VIS spectra at room temperature 
with increasing time: after 72 h the % of variation at 370 nm is less than 10% 
which indicates that the complex is moderately stable in aqueous solution.  
 
  
Figure 16. Stability of RuC in water, Left. Variation UV-VIS spectra with increasing time (in min, 
darker shade to lighter shade)  for the complex RuC in water during 72 h (room temperature, in the 
dark),Right, change ( % of variation (Equation 24)) at 370 nm for a period of 25 h: A maximum of 
10% of variation is observed after 25 h. 
 
Although water is a good solvent for RuC, the need for a buffered medium for the 
determination of stability constants percludes its use as the aqueous medium for 
the essays. 
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 10 mM HEPES pH 7.4 
 
Figure 17 shows the change observed on the UV-Vis spectra of RuC in 10 mM HEPES 
pH 7,4 with increasing time till 44 hours at room temperature. RuC is very stable in 
this medium: only negligible differences were observed in the spectra up to 
approximately 30 h (Figure 17, inset), confirming that the stability of the complex in 
HEPES buffer is adequate for the quantitative determination of binding constants 
as well as for in vitro biological studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. UV-visible spectra recorded over time (44 h) for the complex RuC in the buffer HEPES 
10 mM pH 7,4; inset: Absorbance versus time at several  wavelength values, data for 575 nm are 
indicated in the secondary axis. 
 
The inset shows minimal variations in the values of Absorbance recorded for the 
main wavelengths along the 44 hours of the study, indicating that the complex is 
quite stable in 10 mM HEPES pH 7,4.  
 
The absorbance at 420 nm (a MLCT band, quite representative of changes 
surrounding the metal ion Ruthenium) shows negligible changes during the 44 
hours of the study, which means that HEPES is a suitable buffer to study these 
systems. 
 
This stability test was performed at room temperature and in absence of light.  
 
5.2.0. Time-dependence of the interaction between RuC and HSA 
 
It is essential that the system under study is in thermodynamic equilibrium 
conditions for the accurate determination of any binding constants. As such, the 
time dependance for the interaction at study must be evaluated to establish the 
incubation time. The most suitable incubation time will combine the requirement 
of the system being in equilibrium with experimental feasibility. Time dependance 
for the RuC-HSA system was monitored by UV-VIS absorption and steady-state 
Fluorescence, and the results are included in Figure 18 and Figure 19 respectively. 
 
 
0
0,01
0,02
0,03
0,04
0,05
0,06
0
0,5
1
1,5
0 500 1000 1500 2000 2500 3000
A
b
so
rb
a
n
ce
 
time (mins) 
274 nm 311 nm 350 nm 420 nm 575 nm
0
0,2
0,4
0,6
0,8
1
1,2
1,4
1,6
1,8
230 330 430 530 630 730 830
A
b
so
rb
a
n
ce
 
 (nm) 
t0 t5 t9 t12
t17 t52 t76 1022
t1262 t1469 t2655 (mins)
- 41 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Time dependence for the RuC-HSA system in 10 mM HEPES pH 7,4: evolution of the UV-
Vis absorption spectra of the sample HSA+RuC,  The incubation time (in minutes) is indicated in 
different colours (first measurement in the minute 4 and last measurement in the minute 1473), 
CHSA=4 µM, CRuC=40 µM. Plots A and B show the relative variation of the absorbance  at 385 nm and 
for the MLCT band. 
 
 
Figure 19. Time dependence evolution of the steady-state fluorescence spectra for the RuC-HSA 
system in 10 mM HEPES pH 7,4: the main plot displays the fluorescence emission spectra of the 
sample HSA+RuC until a 24 h contact time, CHSA= 4 µM, CRuC=40 µM. The insets show the relative If 
for the maximum absorbance at 338 nm. 
 
Fluorescence emission spectra recorded for the system RuC-HSA over a 24h period 
are included in Figure 19. The inset shows the relative variation of the Trp214 
emission intensity at 338 nm with time. There is a great decrease in the emission 
intensity in the first minutes of contact with RuC, indicating that the interaction 
occurs quite fast: after 10 min IF decreases to ~20% of the intensity initially 
recorded for the protein alone (IF0), after 20 min IF decreases to 10% and after 30 
min IF is ~8% of the initially recorded signal. After ~210 min (3,5h) changes in the 
emission spectrum become less intense until ~400 min when equilibrium is fully 
reached with %IF ~2,5%. 
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A 24h-incubation period was chosen to combine the need to assure that the 
thermodynamic equilibrium was reached and experimental feasibility. The best 
approach to rationalize the experimental time was to incubate the samples the day 
before measuring. 
 
5.3.0. The system RuC-HSA 
 
The binding of RuC to albumin (fafHSA) was monitored by fluorescence 
spectroscopy using Trp214 as the protein intrinsic fluorescence probe. 
 
The quality of experimental data recorded from fluorescence experiments requires 
much attention to experimental details. It is important to evaluate whether RuC 
has intrinsic fluorescence at the excitation wavelength chosen for Trp214 (295 
nm). It is also important to check whether inner filter / self-absorption effects are 
operative. The plot A shown in Figure 20 displays the absorption spectrum of the 
complex studied (RuC) where the excitation wavelength chosen for the emission is 
indicated (295 nm) and the emission spectrum of the protein is presented. The 
overlap between RuC absorption spectrum and the protein emission spectrum 
shown indicates that the reabsorption of emitted light is likely 60. Therefore, data 
must be corrected for IFE (Equation 3) at both excitation and emission wavelengths 
to account for these aspects that decrease the steady-state fluorescence intensity 
and are not the result of a real interaction 60, 62. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Inner filter effect in 10 mM HEPES pH 7,4: absorption spectrum of the complex RuC 
(CRuC=40 µM) and the emission spectrum of HSA after its excitation at 295 nm (CHSA= 4 µM) (A); 
Emission intensity RuC in the absence of HSA. A decrease of the intensity of the Raman peak is 
shown with increasing concentrations of the complex. exc=295 nm (B). 
    
The Ru(II) complex RuC did not exhibit any intrinsic fluorescence (only the sharp 
Raman peak due to scattered light was seen in the emission spectra) when it was 
excited at 295 nm. It is expected that the Raman peak would have the same 
fluorescence intensity for the different RuC concentrations, which is not the case in 
Figure 20-B: by seeing the different intensities the complex is showing some 
absorption of light, which confirms that the inner filter effect or self-absorption 
corrections are needed.  
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5.3.1. Steady-state fluorescence emission quenching 
 
Fatty-acid-free HSA was used to evaluate the potential of the protein to bind the 
RuII-complex. Steady-state fluorescence emission was measured for the HSA-RuC 
system in several samples prepared from different stock solutions in different 
assays (see Annex A, table 1). Figure 21 and 22 are representative of the results 
obtained in the different measurements. 
 
In the absence of complex, the emission maximum intensity for Trp214 is observed 
at 335 nm, showing that in the protein this residue is protected from the aqueous 
solvent, where Trp would show a maximum emission at ca. 350 nm 60. Figure 21 
presents the effect of increasing concentration of RuC on the protein fluorescence 
emission (in equilibrium conditions):  the complex RuC quenches the fluorescence 
emission intensity of the protein with no shift (within the experimental error) in 
the maximum em (Figure 22-Left). This quenching effect was expected from the 
time-dependence measurements, and it shows that the environment around the 
residue Trp214 is being affected by the presence of RuC, indicating that the 
complex might be binding the protein in the vicinity of Trp214. Further 
experiments with the site markers will help to reveal more details about the 
binding between the protein and the complex. 
 
 
Figure 21. Fluorescence emission spectra for the HSA-RuC system in 10 mM HEPES pH 7,4 (data 
from experiment #8 samples were incubated and measured at 37 ºC. The concentration of the 
complex studied varied from 2 µM (darkest shade) to 48 µM (lightest shade), the CHSA= 2 µM was 
kept constant for each sample during the whole experiment; the red discontinuous line is the 
protein alone emission. 
 
In this study, fatty-acid-free HSA was used to evaluate the potential of the protein 
to bind the RuII-complex. In the absence of complex, the emission maximum 
intensity for Trp214 is observed at 335 nm, displaying that in the protein this 
aminoacid residue is protected from the aqueous solvent, where Trp would show a 
maximum emission at ca. 350 nm 60. Figure 21 presents the effect of the increasing 
concentration of RuC on the fluorescence of the protein: displaying the quenching 
of the fluorescence emission of the protein with no shift in the maximum em 
(Figure 22-Left). 
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Figure 22. Left, Relative fluorescence intensity for the HSA-RuC system (data from experiment #8) 
at 338 nm in 10 mM HEPES pH 7,4 before and after the inner filter effect correction, right Emission 
spectra for the HSA-RuC system normalized at  338 nm (data from experiment #8). 
 
From Figure 22 some conclusions can be highlighted: 22-left the quenching achieved 
by the complex at the maximum concentration tested (48 µM) reaches 10% which 
shows that the complex is binding to the protein quite strongly and changing the 
environment of Trp214, 22-right shows the normalized spectra of the experiment 
#8 without any displacement of the wavelength. 
 
It is important to access the quenching mechanism involved in this interaction, and 
for that purpose time-resolved fluorescence experiments are needed. 
 
5.3.2. Time-resolved fluorescence measurements. 
 
In a time-resolved or fluorescence lifetime measurements, a fluorescence emission 
decay is obtained after a very short excitation pulse, and the emission intensity 
decreases with time according to a sum of exponentials (see section 3.2.3.). 
 
The fluorescence intensity decay with time was recorded for all the samples of the 
binary system HSA–RuC, which were measured and incubated at 37 ºC. Two 
illustrative decay examples (for HSA in the absence of RuC and for HSA at the 
highest concentration of RuC tested) are displayed in Figure 23. This figure shows 
that the decay becomes faster (indicating a shorter fluorescence lifetime) in the 
presence of the complex.  
 
A sum of three exponentials was needed to achieve the best fit shown in Figure 23, 
which is a typical behaviour for Trp214 residues of proteins 60. The following 
parameters were used to obtain the best fit in the top plot: (1) For HSA alone: α1= 
0,29; α2=0,32; α3=0,39,  1=0,79 ns;   2=4,05 ns;   3=7,37 ns (χ2=1,305); (2) for HSA 
plus complex RuC 48 μM: α1= 0,75;  α2=0,20;  α3=0,05;   1=0,39 ns;   2=1,87 ns;  
 3=5,64 ns (χ2=1,200). The randomly distributed residuals of both fits are shown 
in the bottom plot in Figure 23. Further details on the lifetime measurements – such 
as values obtained for αi and for  i in each sample measured – are included in Annex 
D, Table 1. 
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Figure 23. Fluorescence intensity decay of HSA (Trp214) in the absence (dark blue) and in the 
presence (light blue) of  RuC  (48 μM) measured by the single photon counting technique (data 
from experiment #8) in 10 mM HEPES pH 7,4. The lines are the best fit of a sum of three 
exponentials (for further details, see Annex D). The bottom plot shows the residuals from the best 
fits for both samples. The experimental conditions were as follows: CHSA= 2 μM, kept constant; 
samples prepared in 10 mM HEPES buffer pH 7,4; 23,2 h incubation at (37,0 ± 0,5) ºC; 
measurements at (37,0 ± 0,5) ºC. 
 
RuC therefore behaves as a quencher of the Trp214 fluorescence of HSA, and a 
Stern-Volmer plot combining steady-state and time-resolved fluorescence is very 
useful to evaluate the nature of this quenching process. 
 
5.3.3. Stern-Volmer analysis – the quenching mechanism 
 
The Stern-Volmer analysis was performed for each assay and (whenever possible) 
for the average of three replicate experiments. The results were organized 
according to the different concentration of protein used. A higher concentration of 
protein resulted in a better signal-to-noise ratio and in a more intense fluorescence 
signal. However, to comply with the requirement of keeping the optical density of 
the sample low, a higher concentration of protein also limits the maximum 
concentration of RuC that can be used.   
 
 CHSA= 2,0 µM 
 
Figure 24 summarizes the results obtained for the HSA-RuC system from 
experiments #7 to #9, and includes the average experimental points thus obtained. 
In experiments #7 and #8 samples were incubated and measured at 37 ºC; 
experiment #9 was incubated at 37 ºC but measured at room temperature due to 
electrical problems; however, the results from experiment #9 are comparable with 
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those from #7 and #8 and therefore were included in the average executed (Figure 
24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Relative fluorescence intensity for the system HSA-RuC in 10 mM HEPEs pH 7,4 at 338 
nm: Left-relative fluorescence intensity for each one of the independent experiments #7, #8 and 
#9,(CHSA= 2 µM). Right-relative fluorescence intensity averaged from these three experiments 
(standard deviation is included as error bars).  
 
It is quite clear from Figure 24 (left) that the results from experiments #7, #8 and #9 
are mostly very precise and reproducible, which indicates that data measured is of 
high quality as they were obtained from three different experiments (prepared 
from three different stock solutions of both fafHSA and complex). Figure 24 (right) 
shows the average of the experiments presented in 24-left with their error bars 
(some points are the average from #7 and #8; and also some other points come 
from only #9).   
 
In order to determine the quenching mechanism involved in this interaction a 
Stern-Volmer plot analysis is needed. A typical plot is shown in Figure 25 for 
experiments #7, #8 and #9. Stern-Volmer fits (and values of KD and KS) obtained 
for other experiments are included in Annex B.  
 
The intensity IF emitted at 338 nm was used to build the Stern-Volmer plot in 
Figure 25. This wavelength was chosen because it is near the maximum emission 
wavelength (sensitivity is close to maximum), but it is further to the red from the 
water Raman scattering peak. Therefore, the signal-to-background ratio is much 
more favourable than it would be if the real maximum emission wavelength was 
used.  
 
It can be clearly observed that the Stern-Volmer plot for HSA quenching by RuC is 
well described by a quadratic equation, which shows that there is more than one 
quenching mechanism. Since If one of the quenching processes also affects the 
fluorescence lifetime, then the mechanism will implicate both static and dynamic 
quenching processes. 
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Figure 25. Stern-Volmer plots for the steady-state (blue circles) and time-resolved measurements 
(red squares) fluorescence data measured at 338 nm for the system HSA-RuC in 10 mM HEPES pH 
7,4. (Results are from experiments #7, #8 and #9). Error bars indicate the Standard Deviation from 
three replicates. For more information on Stern-Volmer analysis, see Annex B, Table 1. 
 
Considering that the steady-state data are described by a quadratic equation, it can 
be assumed that it involves two separate quenching mechanisms, and the 
relationship shown in Equation 10 is valid. KS and KD from the equation are the 
constants associated with each quenching process. 
 
If the time-resolved Stern-Volmer plot is well represented by a straight line, one of 
the constants (KD, the dynamic quenching constant) can be retrieved from this fit 
(Figures 25 and 27 represented by squares) according to the Equation 16. In fact, the 
Stern-Volmer variation of   with increasing concentrations of RuC is linear (R2= 
0,993 for the average study of #7, #8 and #9). 
 
The intensity emitted at 338 nm was used to build the Stern-Volmer plot 
represented in Figure 25 (and Figure 27). This wavelength was chosen because it is 
near the maximum emission wavelength (sensitivity is close to maximum), but it is 
further to the red taking from reference the water Raman scattering peak, 
therefore, the signal-to-background ratio is much more favourable than it would be 
if the real maximum emission wavelength was used. It can be clearly observed that 
the Stern-Volmer plot for HSA quenching by RuC is well described by a quadratic 
equation, which shows that there is more than one quenching mechanism. If one of 
the quenching processes also affects the fluorescence lifetime, then the mechanism 
will implicate both static and dynamic quenching processes. 
 
Considering that the steady-state data are described by a quadratic equation, it can 
be assumed that it involves two separate quenching mechanisms, and the 
relationship shown in Equation 10 is valid. KS and KD from the equation are the 
constants associated with each quenching process.  
 
If the time-resolved Stern-Volmer plot is well represented by a straight line, one of 
the constants (dynamic quenching constant KD) can be retrieved from this fit 
(Figures 25 and 27 represented by squares) according to the Equation 16. 
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In this study, the Stern-Volmer variation of   with increasing concentrations of RuC 
is in fact linear. The fit of #7, #8 and #9 yields  0/ = (1,01 ± 0,02)+(42,88 ± 0,97) 
x103 Cq (R2=0,993) and to KD= (4,3 ± 0,1)x104 M-1. This constant (KD), which is 
associated with the dynamic quenching mechanism, is quite large (some orders of 
magnitude above the value expected from arbitrary collisions between the 
fluorophore and the complex, generally 10-100 M-1 60, 62). This indicates a 
concentration of quencher in the vicinity of Trp214 higher than the analytical 
concentration of complex in solution, implying its preferential proximity to the 
protein, which is consistent with a ‘loose’ specific interaction of RuC with the HSA.  
The fact that the quenching mechanism affects the fluorescence lifetime of Trp214 
suggests that the complex is still free to move through the protein surface when 
bound, or that its binding is sufficiently loose to keep a considerable degree of 
translational and rotational freedom.  
 
The steady-state fluorescence data are best characterized by the quadratic fit (R2= 
0,997) If0/If = (0,98 ± 0,02) + (5,8 ± 0,4)x104 Cq + (1,22 ± 0,09)x109 Cq2 (the best 
linear fit affords R2= 0,98). Thus, in addition to the dynamic quenching of Trp214 
fluorescence identified upon binding of RuC to HSA, the second process detected is 
static quenching. In order to obtain KS, the value of KD was used in the coefficients 
of Equation 10, and it was calculated then from both (KS+KD) and KSKD relationships. 
In this case the value obtained for KS was (2,8 ± 0,2)x104 M-1. 
 
 CHSA= 2.5 µM 
 
To obtain consistent results, experiments with different concentration of protein 
were performed. 
 
Figure 26 and Figure 27 show the experimental data obtained from experiments #3, 
#4, #5 and #6, and their average. All four experiments were incubated at 37 ºC but 
only #6 was measured at 37 ºC. Experiments #3, #4 and #5 were measured at 
room temperature (~25º) due to problems with the bath for the cell holder in the 
fluorometer. However, the results from experiment #6 are comparable with the 
rest and therefore the average was executed (Figure 26). The quenching achieved 
from the binding between the complex and the protein reaches approximately 
35% when the complex is present at a concentration of 25 μM. 
 
Figure 26-left shows that the results from experiments #3, #4, #5 and #6 are of high 
quality and very reproducible as they are four different experiments prepared 
from four different stock solutions for fafHSA and complex that have yielded very 
similar data. Figure 26-right, shows the average from the experiments presented in 
26-left with the error bars (some points are the average from the four experiments, 
other points are the average from #4, #5 and #6 and also some other points come 
from only #3).  
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Figure 26. Relative fluorescence intensity at 338 nm for the system HSA-RuC in 10 mM HEPES pH 
7,4 at 338 nm: Left-relative fluorescence intensity for each one of the independent experiments #3, 
#4, #5 and #6,(CHSA= 2,5 µM). Right-relative fluorescence intensity averaged from these four 
experiments (standard deviation is included as error bars). 
 
The intensity IF emitted at 338 nm was used to build the Stern-Volmer plot in 
Figure 27. As explained in sections 3.2.2, 3.2.3, the system HSA-RuC exhibits two 
quenching processes happening simultaneously: according to Lakowicz 60 there is 
a dual mechanism when static and dynamic quenching occurs at the same time. 
 
 
Figure 27. Stern-Volmer plots for steady-state (blue circles) and time-resolved measurements (red 
squares) fluorescence data measured at 338 nm for the system HSA-RuC in 10 mM HEPES pH 7,4. 
(Results are from experiments #3, #4, #5 and #6). Error bars indicate the Standard Deviation from 
four replicates. For more information on Stern-Volmer analysis, see annex B, Table 1. 
 
If the plot for the steady-state measurements would have showed a linear Stern-
Volmer fit, it would have been generally an indication of a single class of 
fluorophores, all equally accessible to the quencher. Following the same approach 
if two fluorophore populations are present and one is not accessible to the 
quencher, the Stern-Volmer plots deviate from linearity towards the x-axis, which 
is the case presented here. 
 
The average of the lifetime experiments measured from #3, #4, #5 and #6 yields a 
Stern-Volmer fit equation:  0/ = (9,9 ± 0,3)x101+(5,6 ± 0,2) x104 Cq and KD= (5,6 
± 0,2)x104 M-1 (R2= 0,995)  
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Steady-state fluorescence data are best described by the quadratic fit (R2= 0,997) 
If0/If = (1,04 ± 0,02) + (2,9 ± 0,4)x104 Cq + (1,8 ± 0,2)x109 Cq2 (the best linear fit 
only affords R2=0,97). Following the same procedure as for CHSA= 2 μM, KS was 
calculated as Ks= (3,2 ±0,3)x104 M-1. 
 
An average of the values obtained for the Stern-Volmer quenching constants from 
the different measurements yields: KD= (4,8 ± 0,3) M-1 and KS= (2,3 ± 0,7) M-1 for 
the system HSA-RuC in 10 mM HEPES pH 7,4 after an incubation period of 24 h at 
37 ºC. 
 
A critical point to consider is that the substitution of the equilibrium 
concentrations by total concentrations (analytical concentrations) in data 
processing for the Stern-Volmer approach may not provide trustworthy stability 
constants. This drawback is overcome with calculations using the program 
PSEQUAD, but the Stern-Volmer constants calculated might not be comparable 
with PSEQUAD thermodynamic binding constants. 
 
5.3.4. Calculation of the binding constants with PSEQUAD 
 
Conditional binding constants (' global formation constants) for the system HSA-
RuC can be calculated with PSEQUAD. The program affords not only the global 
formation constants involved but also the stoichiometry of the protein-complex 
adducts formed by solving the mass-balance equations for the system and 
calculating the equilibrium concentrations of RuC and protein from their total 
concentrations in solution.  
 
PSEQUAD was used in all experimental data sets to determine the best binding 
model for the HSA-RuC system in the experimental conditions used: 10 mM HEPES 
pH 7,4 at 37ºC after a 24h incubation period. Adducts with a 1:2 protein:RuC 
stoichiometry typically require higher concentrations of complex to be detected 
from experimental data, and in fact log β’ values can be calculated yielding a good 
fit from long-titration data with PSEQUAD. Values obtained with PSEQUAD for the 
conditional stability constants for the different experimental sets are summarized 
in Annex C, Table 1. The results obtained with PSEQUAD are robust in the sense that 
a minimum is always reached and for different initial values for the calculation, 
the program gives back the same log ’ values within the SD or experimental error. 
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Adduct 
stoichiometry 
T(ºC)* 
CHSA (µM) 
PSEQUAD 
 log β ± SD 
PSEQUAD  
log K  ± SD 
Stern-Volmer 
log KD; log KS  
#1 
HSA-RuC RT  
5,12 
log β1= 4,38 ± 0,01 log K1=4,38 ± 0,01 4,11 ; 4,42 
HSA-(RuC)2 log β2= 8,53 ± 0,07 log K2= 4,15 ± 0,07 
#2 
HSA-RuC 36,9  
2,24 
log β1= 4,72 ± 0,01 log K1= 4,72  ± 0,01 N/A 
HSA-(RuC)2 N/A N/A 
#3 
HSA-RuC RT  
2,51 
log β1= 4,67 ± 0,01 log K1=4,67  ± 0,01 4,41 ; 4,12 
HSA-(RuC)2 N/A N/A 
#4 
HSA-RuC RT  
2,50 
log β1= 4,74 ± 0,01 log K1=4,74  ± 0,01 4,41 ; 4,35 
HSA-(RuC)2 log β2= 9,45 ± 0,02 log K2= 4,71  ± 0,02 
#5 
HSA-RuC RT  
2,51 
log β1= 4,71 ± 0,01 log K1= 4,71  ± 0,01 4,41 ; 4,35 
HSA-(RuC)2 N/A N/A 
#6 
HSA-RuC 36,9  
2,50 
log β1= 4,76 ± 0,01 log K1= 4,76  ± 0,01 
4,78 ; 4,30 
HSA-(RuC)2 N/A N/A 
#7 
HSA-RuC 36,9  
2,00 
log β1= 4,81 ± 0,01 log K1=4,81  ± 0,01 4,61 ; 4,38 
HSA-(RuC)2 log β2= 9,34 ± 0,02 log K2= 4,53  ± 0,02 
#8 
HSA-RuC 36,9  
2,00 
log β1= 4,776 ± 0,005 log K1=4,776  ± 0,005 4,71 ; 4,36 
HSA-(RuC)2 log β2= 9,402 ± 0,012 log K2=4,626  ± 0,013 
#9 
HSA-RuC RT  
2,00 
log β1= 4,90 ± 0,01 log K1=4,90  ± 0,01 4,66 ; 4,35 
HSA-(RuC)2 log β2= 10,24 ± 0,02 log K2=5,34  ± 0,02 
#12 
HSA-RuC 37  
2,00 
log β1= 4,93 ± 0,01 log K1=4,93  ± 0,01 4,93 ; 4,48 
HSA-(RuC)2 log β2= 9,74 ± 0,02 log K2=4,81  ± 0,02 
#19 
HSA-RuC 37  
2,00 
log β1= 4,42 ± 0,01 log K1=4,42  ± 0,01 4,59 ; 4,39 
HSA-(RuC)2 log β2= 9,57 ± 0,01 log K2=5,15  ± 0,01 
Table 2. Conditional stability constants obtained from PSEQUAD and Stern-Volmer analysis for the 
system HSA-RuC at 37 ºC in 10 mM HEPES pH 7,4 after an incubation period of 24h. *Tm is the 
sample temperature during the measurement; all samples in the assays indicated were incubated 
for 24h at 37 ºC before the measurements. Fitting parameters values for all fits are presented in 
Annex C.  
 
From the experimental data gathered in this work, two models can be proposed 
with the computer program PSEQUAD: model 1, predicting the formation of a 
single 1:1 {HSA-RuC} adduct, and model 2 with adducts with 1:1 and 1:2 
stoichiometries. These are presented in Table 3. The fitting parameter is very 
similar for both models and low SD values are obtained in both cases which makes 
it difficult to choose between the two. 
 
From the time-resolved fluorescence measurements two different quenching 
processes were identified. Although these processes can indicate either the 
formation of two distinct adducts or the existence of two different types of binding 
interaction of RuC with albumin, those results offer further support to a model 
with the formation of two complex-protein adducts. In fact, the log K’ values 
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obtained with PSEQUAD for {HSA-RuC} and {HSA-(RuC)2} adducts, and the Stern-
Volmer constants Ks and KD constants obtained are quite comparable (see Table 2).  
 
 log β’ (± SD) log K’binding  
Model  1 Model 2 Model 2 
HSA–C 4,72 (± 0.01) 4,78 (± 0.01) 4,78  
HSA – C2 ´---- 9,40 (± 0.01) 4,62 
RuC concentration range  
HSA concentration  
slits 
0-10 µM 
2,24 µM 
2 nm 
0-48 µM 
2,00 µM 
2 nm 
 
 
- 
Fitting parameter 9,7 x 104 8,9 x 104 - 
Number of points 9 
 
16 - 
ºC of freedom 1168 2336 - 
Table 3. Conditional binding constants (log β’) and log K’binding at 37 ºC calculated from the steady-
state fluorescence measurements for the system RuC-HSA in 10 mM HEPES for the two binding 
models proposed. Details on the fit for all measurements are included in Annex C. 
 
5.3.5. Speciation model for the system RuC-HSA 
 
The evaluation of the species that can form in a system and of their stability 
constants allows plotting equilibrium concentration distribution curves for the 
system in different conditions.  
 
Figure 28 presents the speciation of HSA and RuC in the experimental conditions 
used for the fluorescence measurements and blood conditions for the two models 
presented in Table 3:. The formation of two species in 10 mM HEPES pH 7,4 (CHSA= 
2,0 µM,) can be confirmed: as it is shown in Figure 28-B, {HSA-RuC} is basically 
formed as soon as the complex makes contact with the protein; however, in the 
case of {HSA-(RuC)2} the species is seen when it reaches about 20% of the 
formation relative to HSA and this occurs approximately when the complex in 
solution reaches a concentration of about 15 µM. Some experiments were 
performed with a maximum concentration of complex of 10-12,5 µM (#2, #3), and 
this explains why those models proposed from PSEQUAD do not show the 
formation of HSA-(RuC)2. 
 
From Figure 28 it is interesting to note that, although the two adducts may form in 
some experimental conditions, in blood serum (with an albumin concentration of 
~630 µM) the species {HSA-(RuC)2} it is not very relevant since its formation is 
negligible. Therefore, even though the formation of two complex-protein adducts 
is possible, only the 1:1 adduct {HSA-(RuC)} is relevant in the context of the 
distribution of RuC by albumin binding in the blood plasma. 
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Figure 28. Speciation diagrams for the system HSA–RuC in 10 mM HEPES pH 7,4 at 37ºC. A, B: 
concentration plots obtained with Model 2 for the albumin concentration in the blood and for the 
fluorescence experimental conditions where HSA-C and HSA-C2 refer to the two adducts formed 
with complex RuC (total concentration of C is in Molar). C, D: concentration plots obtained with 
Model 1 for blood conditions and for the experimental conditions; These diagrams were obtained 
with the HySS computer program using the conditional binding constants in table 3. 
 
5.4.0. Characterization of the binding sites of RuC on HSA. 
Researchers have shown a remarkable interest in determining the binding sites of 
metallodrugs on biomolecules in order to improve the design of future drug 
candidates 42.  
For most drugs, the binding sites of HSA are located in hydrophobic cavities in 
subdomains IIA and IIIA, designated as Sudlow’s drug binding site I (in domain IIA) 
and drug binding site II (in domain IIIA). These interactions are normally quite 
fast, in contrast with a covalent type of binding, which usually takes a long time to 
reach equilibrium. Trp214 is located very near to the drug binding site I, and a 
strong quenching of its fluorescence is usually interpreted as an indication that the 
compound is binding at site I. Nevertheless Trp214 emission can be sensitive to 
changes occurring at site II as well 68. 
Covalent binding to the side chain residues of the protein is possible and was 
reported for Ru complexes that have a labile ligand (typically a Cl-) in the 
coordination sphere. However, RuC is is stable in solution and does not undergo 
ligand exchange processes easily because RuC has no labile ligands (such as Cl-, as 
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in the case of KP1019 or in RAPTA complexes).  Thus covalent binding to HSA 
(which would imply the loss of one of the co-ligands) is not expected to be an 
important component of the binding process in the HSA–RuC system. 
Displacement reactions were done to elucidate RuC binding sites on HSA using the 
established site markers warfarin (WF) and dansylglycine (DG). WF was used as 
site marker for site I and DG was used as a site marker for site II. Because self-
absorption of RuC is significant, the correction of the emission intensity with the 
IFE equation (Equation 3) was needed. 
 
5.4.1. Warfarin (drug binding site I, domain II) 
 
Fluorescence monitoring of competitive binding to HSA with Warfarin is often 
used to determine whether a given ligand/metal complex binds to Sudlow´s Site I. 
Normally, the displacement of warfarin from its HSA complex {HSA-WF} is easily 
observed by a decrease of the fluorescence intensity, when the adduct formed 
between the metal complex and the protein is “stronger” than the {WF-HSA} 
complex. 
 
Steady-state fluorescence data for the system HSA-W-RuC was evaluated using 
PSEQUAD. The binding process of WF to HSA was assessed in the experimental 
conditions used for the HSA–RuC system. Warfarin alone emission, titrations of 
HSA with warfarin, and titrations of the adduct {HSA-W} with RuC were done. 
Figure 29 shows the fluorescence emission intensity at 375 nm (exc=310 nm) for 
all these systems.  
 
Figure 29. Fluorescence emission intensity (exc= 310 nm) at the maximum wavelength (375 nm), 
for the species involved in the ternary system. HSA-WF-RuC in 10 mM HEPES pH 7,4 (Experiments 
#23, #24 and #25- see Annex A3, Table 1) 
 
 HSA-WF System: 
 
Figure 30 shows fluorescence emission spectra for the components of the HSA-WF 
system. Warfarin has weak fluorescence emission when samples are excited at 
310 nm. The addition of HSA causes a marked an increase in the emission intensity 
due to the binding of the site marker to the protein forming the 1:1 adduct {HSA-
WF}. In plot B normalized spectra of HSA alone, Warfarin and {HSA-WF} show an 
evident displacement of 9 nm in the em maximum of Warfarin upon binding to 
HSA. 
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Figure 30. The HSA-WF system. A-Fluorescence emission spectra of WF (CWF= 40 μM) and HSA-WF 
(CHSA= 2 μM, CWF= 40 μM); B- Normalized fluorescence emission for HSA, Warfarin, HSA-WF, where 
the displacement from the bands could be appreciated (10 mM HEPES pH 7,4, 37 ºC, exc= 310 
nm). 
 
 HSA-WF-RuC System: 
 
Figure 31 presents the emission spectra recorded for the system HSA-WF-RuC. The 
intensively emitting 1:1 adduct {HSA-WF} is titrated with RuC and the addition of 
complex decreases the intensity of the fluorescence emission.  
 
 
Figure 31. Emission spectra of the system HSA-WF-RuC, experiment #28 (see Annex A3, Table 1 
for further details), the dashed line represents the adduct HSA-WF in equimolar conditions (C= 2 
μM), the straight lines represent the system {HSA-WF}-RuC in increasing concentrations (varying 
from the darkest shade at the lowest concentration of RuC, CRuC= 2 μM to the lightest shade at the 
highest concentration of complex studied, CRuC= 44 μM). 
 
Figure 32, shows that the initial intensity of the adduct {HSA-WF} decreased by 
about 20% upon addition of the complex RuC (until a concentration of 44 µM). 
This decrease of intensity was accompanied by a small shift (Figure 32-B) that is 
normally associated with the increasing free Warfarin due to its displacement 
from the binding pocket.  
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Figure 32. A: relative fluorescence intensity for the ternary system HSA-WF-RuC at its maximum 
wavelength (375 nm) (data of the experiment #28, corrected for IFE - see Annex A for further 
details);  B:  Normalized spectra from the same experiment as in plot A exhibiting a blue-shift; red 
line represents emission of the adduct HSA-WF in equimolar conditions, and the blue lines emission 
of the adduct HSA-WF with increasing concentrations of RuC. 
 
These results are consistent with the displacement of WF from the binding pocket 
of the protein caused by the complex, which indicates that binding of the complex 
to Sudlow´s site I is probably occurring. Therefore, the displacement of the site 
marker at various concentrations of RuC could be followed via intensity changes of 
the emission spectra. 
 
In case of the system shown on Figure 32-A (experiment #28), the initial intensity 
of the adduct {HSA-WF} decreased by about 25% upon addition of the complex 
RuC with a concentration of 44 μM. This decrease of intensity was not 
accompanied by a shift in the emission maximum (within the experimental error) 
(Figure 32-B). These results are consistent with a considerable displacement of WF 
from HSA upon addition of complex, indicating that RuC can bind at drug binding 
site I in HSA. 
 
It is important to highlight that the displacement of the site marker can be 
measured when the ligand binds at the binding site of the marker compound. 
However, if its binding constant is much lower compared to that of the site marker 
only a high excess of the ligand can result in a detectable effect.  
 
PSEQUAD 
 
Conditional binding constants for the experiments involving the Warfarin ternary 
system were calculated with PSEQUAD, and the results of the average of the 
experiments are shown in Table 4. Experimental data for WF alone, WF-HSA and 
HSA-WF-RuC was averaged and evaluated within the same input file. Log ’ values 
for the formation of HSA-WF and HSA-RuC were then calculated, and results are 
included in Table 4. 
 
The conditional binding constant calculated for WF from the HSA-WF binary 
system was log ’(WF) = log  K’(WF)= (6,02 ± 0,01) (Table 4). It was found to be in 
fairly good agreement with values in the literature 42, 57. The samples for the 
experiments executed in this thesis did not include salt (to keep the ionic strength 
of the medium constant) because of the very low solubility of RuC in the presence 
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of inorganic salts, which cause strong precipitation. Therefore, the differences 
between the constants obtained in this study and the literature data are likely to 
be due to these experimental variations. 
 
HSA-WF-RuC System CHSA/ μM CWF/ μM CRuC / μM Adduct  log β’ ± SD  FP 
Minimum 
reached? 
a
v
e
ra
g
e
 f
il
e
 
WF alone - 0-40 - - 
2,67x105 Yes 
WF+HSA 2 0-40 - (HSA-WF) 6,02 ± 0,01 
WF+HSA+RuC 2 2 0-44 
 (HSA-WF):6,075 ± 0,003                     
(HSA-RuC):5,614 ± 0,005                 
Table 4. Average values for the conditional binding constants of species involved in the ternary 
system HSA+WF+RuC calculated with the program PSEQUAD from fluorescence emission data in 
10 mM HEPES pH 7,4 at 37 ºC.  
 
It was possible to calculate conditional formation constants for the 1:1 adduct 
{HSA-RuC} and for the {HSA-WF} adduct (together) from the experimental data 
with a very low standard deviation and a good fitting parameter. Log β’ for the 
adduct {HSA-WF} calculated from the ternary system (in the presence of RuC) is 
fairly the same as the value obtained from the binary system. In what concerns the 
Log β’ for the adduct {HSA-RuC} the value calculated from the ternary system is a 
bit higher than that obtained from the binary system HSA+RuC.  
 
The reason for the overestimation of the {HSA-RuC} formation constant may be 
that there seems to be an interaction between the two. A fluorimetric titration of 
warfarin with RuC (see Annex A3, Figure A) showed that the intrinsic fluorescence 
of WF decreases with increasing concentrations of complex. The partial overlap 
between the absorption spectrum of RuC and the emission spectrum of WF (see 
Annex A3, Figure B) suggests that a mechanism of energy transfer between these 
two species might be operative. Another possibility is that RuC may be losing one 
of its co-ligands to bind WF. In fact, the complex is stable enough in aqueous media 
but the stability in the presence of a competitive ligand was not checked yet and 
this hypothesis cannot be discarded based on the data collected in this work  
 
Figure 33 and Figure 34 show the different species present in the HSA-WF-RuC 
system. 
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Figure 33. Fluorescence emission spectra of all the species involved in the HSA-WF-RuC system. 
(Dashed lines represent the maximum intensity for each set, each is represented by a different 
colour (data from experiments #23, #24 and #25- see Annex A3, Table 1 for more details). 
 
.  
 
Figure 34. Normalized fluorescence emission spectra of all the species involved in the HSA-WF-
RuC system (from Figure 33, from experiments #23, #24 and #25- see Annex A3, Table 1) for more 
details). 
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5.4.2. Dansylglycine (drug binding site II, domain III) 
 
In this section, fluorescence monitoring of competitive binding to HSA with DG 
was used to evaluate the binding at Sudlow´s Site II. As in the case of warfarin, the 
displacement of DG from its HSA complex {HSA-DG} is observed by a decrease of 
the sample fluorescence intensity. 
 
Steady-state fluorescence emission for the system HSA-DG-RuC was evaluated 
using PSEQUAD. The binding process of DG to HSA was assessed in the 
experimental conditions used for the HSA–RuC system: 10 mM HEPES pH 7,4. 
Dansylglycine alone measurements, titrations of HSA with DG and titrations of the 
1:1 adduct {HSA-DG} with RuC were done. Figure 35 shows the fluorescence 
emission intensity at 490 nm (exc=335 nm) recorded for all these systems. It is 
very visible that the increase in DG concentration makes the adduct´s {HSA-DG} 
fluorescence emission more intense. However, in the case of the ternary system 
HSA-DG-RuC the emission fluorescence intensity decreases when the 
concentration of complex is increased.  
 
 
Figure 35. Emission fluorescence intensity (exc=335 nm) at the maximum wavelength (490 nm), 
for the species involved in the ternary system HSA-DG-RuC in 10 mM HEPES pH 7,4. (Experiments 
#33, #34 and #35-See Annex A4, Table 1) 
 
 HSA-DG System: 
 
Figure 36 shows the fluorescence emission spectra of DG (CDG=40 μM) and HSA-
DG (CHSA= 2 μM, CDG=30- 40 μM).  
 
Dansylglycine has negligible fluorescence emission when the sample is excited at 
335 nm (see Figure 35). The addition of protein causes an increase in the 
emission intensity and a great shift in the emission maximum of more than 70 nm 
due to the binding of the site marker to the protein (at Sudlow´s site II).  
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Figure 36. Fluorescence emission spectra of DG (CDG=40 μM) and HSA-DG (CHSA= 2 μM, CDG=(30- 40 
μM)) and (right) normalized fluorescence intensity for the different species such as DG, HSA-DG 
and HSA, where the displacement from the bands could be easily seen. (37 ºC, 10 mM HEPES pH 
7,4, exc=335 nm)  
 
 
 HSA-DG-RuC System: 
 
Figure 37 shows the emission spectra recorded for the system HSA-DG-RuC. The 
highly fluorescent 1:1 {HSA-DG} adduct is titrated with RuC, and a marked 
decrease in the intensity of the fluorescence emission upon the addition of 
complex is observed.  
 
 
Figure 37. Emission spectra of the system HSA-DG-RuC, experiment #35 (see Annex A4, Table 1 
for further details), the dashed line represents the adduct HSA-DG in equimolar conditions 
(CHSA=CDG= 2 μM), the straight lines represent the system {HSA-DG}-RuC in increasing 
concentrations (varying from the darkest shade at the lowest concentration of RuC, CRuC= 2 μM to 
the lightest shade at the highest concentration of complex studied, CRuC= 36 μM). 
 
Figure 38 shows that the initial intensity of the {HSA-DG} adduct decreases by 
about 11% upon addition of the complex RuC (until a concentration of 36 μM). 
This decrease of intensity is accompanied by the development of a band at higher 
wavelength values, consistent with the presence of a high enough concentration of 
free DG. The data shows that considerable displacement of DG takes place upon 
addition of complex, showing that this complex might be binding at the drug 
binding Site II of HSA.  
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Figure 38. Left, shows the relative fluorescence intensity for the ternary system HSA-DG-RuC of the 
experiment #35(see Annex A, Table 1 for further details), at its maximum wavelength (490 nm). 
Right, Normalized spectra from the same experiment as in the left plot with a clear change in the 
bands at higher concentrations of complex, red continuous line represents the adduct HSA-DG in 
equimolar conditions and the blue lines the adduct HSA-DG with increasing concentrations of RuC. 
 
PSEQUAD 
 
As in the case of the warfarin site-marker, conditional formation constants for the 
experiments in the dansylglycine ternary system were calculated with PSEQUAD, 
and the results of the average of the experiments are shown in Table 5. 
Experimental data for DG alone, DG-HSA and HSA-DG-RuC was averaged and 
evaluated within the same input file. The average was made from three 
independent experiments. Log ’ values for the formation of HSA-DG and HSA-RuC 
were then calculated, and results are included in Table 5.  
 
The conditional constant calculated for the binding of DG to HSA using data from 
the HSA-DG binary system was log ’(DG) = log  K’(DG)= (5.47 ± 0,01), which is in 
fairly good agreement with the values in the literature 42, 57 considering the slight 
differences in the experimental conditions (absence of the inorganic salt). 
 
HSA-DG-RuC System CHSA/ μM CDG/ μM CRuC / μM Adduct log β’ ± SD  FP 
Minimum 
reached? 
a
v
e
ra
g
e
 f
il
e
 
DG alone N/A 0-40 N/A N/A 
5,85x106 Yes 
DG+HSA 2 0-40 N/A (HSA-DG): 5,47 ± 0,01 
DG+HSA+RuC 2 2 0-44 
(HSA-RuC):5,04 ± 0,04                             
(HSA-DG)= 5,64 ± 0,03                             
Table 5. Average values for the conditional binding constants of species involved in the ternary 
system HSA+DG+RuC calculated with the program PSEQUAD from fluorescence emission data in 10 
mM HEPES pH 7.4 at 37 ºC.  
 
It was possible to simultaneously calculate conditional formation constants for the 
1:1 adduct {HSA-RuC} and for the {HSA-DG} adduct from the experimental data. 
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Log β’ for the adduct {HSA-DG} calculated from the ternary system (in the 
presence of RuC) is in fairly good agreement with the value obtained from the 
binary system. In what concerns the Log β’ for the adduct {HSA-RuC} the value 
calculated from the ternary system is quite close to that obtained from the binary 
system HSA+RuC.  
 
This results further support that the RuC seems to be displacing DG from its 
binding site on HSA and possibly might be binding at the drug binding Site II of 
HSA. 
 
 
Figure 39. Shows the absorption spectrum of the complex and the emission spectrum of the site 
marker Dansylglycine. 
 
Figure 40 and Figure 41 show the different species present in the HSA-DG-RuC 
system. 
 
 
Figure 40. Fluorescence emission spectra of all the species involved in the HSA-DG-RuC system. 
(Dashed lines represent the maximum intensity for each set of species, each set of species is 
represented by a different colour, experiments #33, #34and #35). 
 
 
 
0
0,2
0,4
0,6
0,8
1
250 350 450 550
If
 o
r 
A
b
so
rb
a
n
ce
 (
a
.u
.)
 
Wavelength (nm) 
DG alone 
RuC absorption 
spectrum 
0
10000000
20000000
30000000
40000000
50000000
60000000
310 360 410 460 510 560
If
 (
a
.u
.)
 
Wavelength (nm) 
HSA-RuC 
HSA-DG 
DG 
HSA-DG-RuC 
- 63 - 
 
 
Figure 41. Normalized spectra from Figure 40. 
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5.5.0. Conclusions 
The binding of an organometallic ruthenium(II) complex to human serum albumin 
was evaluated in this work. The interaction of the piano-stool complex 
[RuII(Cp)(bipy)(CO)][PF6] (or RuC) with fatty acid free human serum albumin at 
pH 7,4 in 10 mM HEPES at 37ºC was monitored by spectroscopic methods (UV-Vis 
absorption and Fluorescence spectroscopy). This complex is a water-soluble with a 
moderate cytotoxic activity against human ovary carcinoma.  
The binding process was observed in the changes recorded for UV-Visible spectra 
for the HSA-RuC system. Steady-state and time-resolved fluorescence spectroscopy 
were used to get quantitative information on the binding interaction, using Trp214 
as a structural fluorescent probe, and selectively exciting this residue. HSA-Trp214 
fluorescence was strongly quenched by the complex RuC by a combination of 
dynamic and static quenching mechanisms with the Stern-Volmer constants KD = 
(4,8 ± 0,3)x104 M-1 and KS = (2,3 ± 0,7)x104 M-1 (obtained for a confidence level of 
95%).  
Formation of adducts with 1:1 and 1:2 stoichiometries for RuC and HSA were 
identified and the corresponding conditional global binding constants were 
calculated using the computer program PSEQUAD:  log ’({HSA-(RuC)} = (4,78 ± 
0,01) and log ’({HSA-(RuC)2} = (9,52 ± 0,01) with a fitting parameter of 1,16x105. 
These conditional global binding constants indicate a moderate binding strength of 
RuC to albumin (in both adducts) and are comparable with those found in the 
literature for KP1019 which is reported to bind to HSA in a moderate and 
reversible manner.  
Displacement reactions using warfarin and dansylglycine as specific markers for 
the HSA drug binding Site I and Site II (respectively) were done to obtain more 
information on the binding of RuC to albumin. Results showed that RuC can 
displace both site markers from their HSA adducts, indicating that it can bind to 
both binding sites on HSA.  
The conditional global binding constants calculated provide a useful speciation 
model for the RuC-HSA system: in blood serum conditions the relative importance 
of the 1:1 and 1:2 adducts is quite different, with the formation of {HSA-(RuC)2 
being negligible. This implies that the 1:2 adduct will be of lesser importance in the 
binding of RuC to HSA, and that the 1:1 adduct will be the prevalent species in the 
blood.  
RuC can thus be efficiently transported in the blood stream through albumin 
binding, forming an adduct with the protein with a 1:1 stoichiometry.  
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6.0. CONCLUDING REMARKS 
 
It is essential to explore the interactions between anticancer metallodrugs and 
serum proteins as these interactions are known to affect in the biodistribution of 
the drug, possibly its mechanism of action and toxicity.  
 
In fact, this is one of the first steps in evaluating the potential of a new drug: if it 
binds too tight to albumin the drug does not exert its effect as it is eliminated; if it 
is not bound tightly enough it cannot be efficiently delivered into the targeted 
tumour tissue and tumour cells. To have a method that yields good quality data 
related to the binding between a transport protein with metallodrugs is important.  
 
The complex studied is not commercially available, and the amount of high purity 
material available was restricted. This implied some limitations in the 
experimental procedure (e.g. at the time of preparing the samples) to comply with 
the requirement of using low amounts of material. Regardless of those limitations, 
very reproducible results were obtained. Fits to the experimental data yielded low 
SD values and very good fitting parameters, thus indicating high quality 
experimental data, adequate for quantitative analysis. All the experiments were 
executed from independent stock solutions that were freshly prepared every day 
herein, demonstrating the good quality data obtained when achieving similar 
results for different experiments that were performed in different days. The 
method accomplished the expected, good fittings, low Standard deviation and 
consistent results. The approach used in this work is thus reliable, has a good 
overall consistency and can be safely used on other metal ion compounds that are 
identified as prospective anti-tumour drugs.  
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7.0. FUTURE PERSPECTIVES 
 
This work yielded the study of the human albumin binding of a prospective anti-
tumour metallodrug, the complex [RuII(Cp)(bipy)(CO)][PF6]. Stoichiometries and 
conditional binding constants for the protein-complex adducts were obtained and 
the interaction was studied with some detail.  
Nevertheless some studies would be of value to disclose more information on this 
system, and/or other techniques would be useful. 
 
From the time dependence studies it is concluded that the equilibrium is achieved 
fast enough for a non-covalent binding process to be operative. The fact that full 
equilibrium was reached between 200 and 400 min could indicate that there is 
some covalent binding component involved in the system studied (because the 
system takes few hours to reach the equilibrium). To study the covalent binding 
between the complex and the protein would be interesting as a complement to this 
work. Experiments with amino acids with the amino-acid binding group blocked 
could be performed so that a possible interaction with the side chain might be 
detected. 
 
From PSEQUAD fits it was possible to refine (in some restricted conditions and 
typically with a lower FP) the formation constant for the ternary species {HSA-site 
marker-complex}. The formation of this possible species was not clear, and the use 
of other techniques – such as e.g. circular dichroism – would provide more insight 
to this topic.  
 
Checking the interaction with amino acids to see if the complex is still stable in 
their presence or if it binds to the amino acid losing one of the co-ligands of the 
parent complex would be another interesting project to undertake. 
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9.0.  ANNEXES 
 
Annex A1. Binary system 
 
 (A1-HSA-RuC system) 
date /        
experiment 
CHSA / M CComplex/M ratio Steady-state measurem. 
Time-resolved 
measurem. 
Tincub /ºC T measurem./ºC (bath) time incub./h 
Emission slits/ 
time-resolved 
emission slits 
8.Oct /#1 
                  
 
5,12x10
-06
 0 0 
If (exc=295 nm)
 
37 RT 19,8 2 nm /8nm 
  
2,50x10-06 0,5  
  
5,01 x10-06 1  
  
1,25 x10-05 2,4  
 
* 2,51 x10-05 4,9  
 
* 5,01 x10-05 9,8  
 
* 7,51 x10-05 14,7  
22.Oct / #2         
  
      
  
 
2,24 x10-06 0 0 
If (exc=295 nm)
 
37 36,9 20,2 2nm/15nm 
  
1,30 x10-06 0,58 - 
  
2,50 x10-06 1,11  
  
3,81 x10-06 1,69 - 
  
5,00 x10-06 2,22  
  
6,29 x10-06 2,79 - 
  
7,50 x10-06 3,33  
B 
 
  
8,74 x10-06 3,88 - 
  
9,99 x10-06 4,43  
25.Oct / #3                   
 
2,51 x10-06 0,0 0 

If (exc=295 nm)
 
 
37 
 
RT 
 
23,3 
 
2nm/10nm 
  
1,30 x10-06 0,52  
  
2,50 x10-06 1  
  
3,80 x10-06 1,51  
  
4,39 x10-06 1,75  
  
6,30 x10-06 2,51  
  
7,50 x10-06 2,99  
  
8,77 x10-06 3,5  
  
1,01 x10-05 4,01  
  
1,25 x10-05 4,99  
29-Oct / #4                   
 
2,5 x10-06 0,00  0 
If (exc=295 nm)
 
37 RT 24,3 2nm/14nm 
  
2,51 x10-06 1 
 
  
5,01 x10-12 2,01  
  
7,50 x10-06 3  
  
1,00 x10-05 4,01  
  
1,25 x10-05 5,01  
  
1,50 x10-05 6,02  
  
1,76 x10-05 7,02  
  
2,01 x10-05 8,02  
  
2,51 x10-05 10,03  
01.Nov / #5                   
 
2,51 x10-06 0,00  0 





  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
2,50 x10-06 1  
  
5,00 x10-06 1,99  
C 
 
  
7,50 x10-06 2,99 


If (exc=295 nm)
  
 
 
37 
 
 
 
RT 
 
 
 
25,8 
 
 
 
2nm/13nm   
9,97 x10-06 3,98  
  
1,25 x10-05 4,99  
  
1,50 x10-05 5,99  
  
1,75 x10-05 7  
  
1,99 x10-05 7,96  
  
2,50 x10-05 9,97  
5.Nov / #6                   
 
2,50 x10-06 0,00  0 
If (exc=295 nm)
 
37 36,9 24,2 2nm/14nm 
  
2,50 x10-06 1,00  
  
4,99 x10-06 2,00  
  
7,52 x10-06 3,01  
  
1,00 x10-05 4,00  
  
1,26 x10-05 5,02  
  
1,50 x10-05 6,01  
  
1,75 x10-05 7,01  
  
2,00 x10-05 8,00  
  
2,25 x10-05 9,00  
  
2,50 x10-05 9,99  
7.Nov / #7                   
 
2,00 x10-06 0 0 


If (exc=295 nm)
 
 
 
37 
 
 
36,9 
 
 
24,0 
 
 
2nm/15nm 
  
2,00 x10-06 1,00 
 
  
2,40 x10-06 1,20  
  
4,01 x10-06 2,00  
  
4,81 x10-06 2,40 - 
  
6,00 x10-06 3,00  
  
8,00 x10-06 4,00  
  
1,00 x10-05 5,00 - 
D 
 
  
1,20 x10-05 6,00  
  
1,40 x10-05 7,00  
  
1,60 x10-05 7,99  
  
1,80 x10-05 8,99 - 
  
2,00 x10-05 9,99 - 
  
2,40 x10-05 11,99 - 
  
2,80 x10-05 13,99  
  
3,20 x10-05 15,99  
  
3,60 x10-05 17,99  
  
4,00 x10-05 19,99 - 
  
4,41 x10-05 22,03  
  
4,80 x10-05 23,98  
12.Nov / #8                   
 
2,00 x10-06 0,00  0,00 
If (exc=295 nm)
 
37 36,9 23,2 2nm/15nm 
  
2,00 x10-06 1,00 
 
  
2,40 x10-06 1,20  
  
4,01 x10-06 2,00  
  
4,79 x10-06 2,40  
  
6,00 x10-06 3,00  
  
8,00 x10-06 4,00  
  
1,00 x10-05 5,00  
  
1,20 x10-05 6,02  
  
1,40 x10-05 6,99  
  
1,61 x10-05 8,03  
  
1,80 x10-05 8,99  
  
2,01 x10-05 10,04  
  
2,40 x10-05 12,01  
  
2,80 x10-05 14,01  
E 
 
  
3,20 x10-05 16,02  
  
3,60 x10-05 17,99  
  
4,00 x10-05 20,00  
  
4,40 x10-05 22,00  
  
4,80 x10-05 24,01  
15.Nov / #9                   
 
2,00 x10-06 0,00  0,00 


If (exc=295 nm)
 
 
 
37 
 
 
RT 
 
 
6,5 
 
 
2nm/15nm 
 
* 2,00 x10-06 1,00 
 
  
2,50 x10-06 1,25  
  
3,01 x10-06 1,50  
  
3,50 x10-06 1,75  
  
4,00 x10-06 2,00  
  
4,51 x10-06 2,26  
  
5,01 x10-06 2,50  
  
5,50 x10-06 2,75  
  
6,00 x10-06 3,00  
  
6,51 x10-06 3,26  
  
7,01 x10-06 3,50  
  
7,51 x10-06 3,75  
  
8,05 x10-06 4,02  
  
8,50 x10-06 4,25  
 
* 9,02 x10-06 4,51  
 
* 9,55 x10-06 4,78  
 
* 1,00 x10-05 5,00  
 
* 1,05 x10-05 5,26  
 
* 1,11 x10-05 5,53  
 
                  
Table 1: Conditions of the experiments performed for the system HSA + RuC. (RT, room temperature; * exc=351 nm + 413 nm + 498 nm, very low emission from the complex at 498; 351/413nm, raman in 
the middle of the emission band) 
F 
 
 A2- Temperature dependence (HSA + RuC system) 
 
date / experiment CHSA / M CComplex/M ratio Steady-state measurem. 
Time-resolved 
measurem. 
Tincub /ºC 
Tmeasure/ºC 
(bath) 
time incub/h 
Emission slits / 
time-resolved 
emission slits 
24.Jan / #10                   
  2,00 x10-06 0,00  0 


If (exc=295 nm)
 
 
 
25 
 
 
25 
 
 
24,1 
 
 
2nm/15nm 
  
 
2,06 x10-06 1,03  
  
 
4,57 x10-06 2,28  
  
 
6,04 x10-06 3,02  
  
 
8,03 x10-06 4,02  
  
 
1,00 x10-05 5,01  
  
 
1,40 x10-05 7,00  
  
 
1,81 x10-05 9,03  
  
 
2,31 x10-05 11,53  
  
 
2,60 x10-05 13,01  
  
 
3,01 x10-05 15,03  
  
 
3,50 x10-05 17,50  
28.Jan / #11                   
  2,00 x10-06 0,00  0 
If (exc=295 nm)
 
25 25 23,5 4nm/15nm 
  
 
2,00 x10-06 1,00  
  
 
4,54 x10-06 2,27  
  
 
6,00 x10-06 3,00  
  
 
7,99 x10-06 4,00  
  
 
9,99 x10-06 5,00  
  
 
1,40 x10-05 7,00  
  
 
1,80 x10-05 8,99  
  
 
2,30 x10-05 11,51  
  
 
2,60 x10-05 12,99  
G 
 
  
 
3,00 x10-05 14,99  
  
 
3,50 x10-05 17,50  
31.Jan / #12                   
  2,00 x10-06 0 0 
If (exc=295 nm)
 
37 36,9 22 4nm/15nm 
  
 
1,99 x10-06 0,99  
  
 
4,52 x10-06 2,26  
  
 
6,05 x10-06 3,03  
  
 
8,04 x10-06 4,02  
  
 
1,00 x10-05 5,01  
  
 
1,40 x10-05 7,00  
  
 
1,81 x10-05 9,03  
  
 
2,30 x10-05 11,52  
  
 
2,60 x10-05 13,01  
  
 
3,00 x10-05 15,00  
  
 
3,51 x10-05 17,53  
31.Jan / #13                   
  2,00 x10-06 0 0 
If (exc=295 nm)
 
20 20 24 4nm/15nm 
  
 
1,99 x10-06 0,99  
  
 
4,52 x10-06 2,26  
  
 
6,05 x10-06 3,03  
  
 
8,04 x10-06 4,02  
  
 
1,00 x10-05 5,01  
  
 
1,40 x10-05 7,00  
  
 
1,81 x10-05 9,03  
  
 
2,30 x10-05 11,52  
  
 
2,60 x10-05 13,01  
  
 
3,00 x10-05 15,00  
  
 
3,50 x10-05 17,53  
H 
 
05.Feb / #14                   
  2,00 x10-06 0 0 

If (exc=295 nm)
 
 
30 
 
30 
 
23 
 
4nm/15nm 
  
 
2,05 x10-06 1,03  
  
 
4,49 x10-06 2,24  
  
 
6,03 x10-06 3,01  
  
 
8,01 x10-06 4,01  
  
 
1,00 x10-05 5,00  
  
 
1,40 x10-05 7,02  
  
 
1,80 x10-05 9,01  
  
 
2,30 x10-05 11,51  
  
 
2,60 x10-05 13,01  
  
 
3,00 x10-05 15,00  
05.Feb / #15                   
  2,00 x10-06 0 0 
If (exc=295 nm)
 
20 20 26 4nm/15nm 
  
 
2,05 x10-06 1,03  
  
 
4,49 x10-06 2,24  
  
 
6,03 x10-06 3,01  
  
 
8,01 x10-06 4,01  
  
 
1,00 x1005 5,00  
  
 
1,40 x10-05 7,02  
  
 
1,80 x10-05 9,01  
  
 
2,30 x10-05 11,51  
  
 
2,60 x10-05 13,01  
  
 
3,00 x10-05 15,00  
28.Feb / #16                   
  2,00 x10-06 0 0 

If (exc=295 nm)
 
 
30 
 
30 
 
22 
 
4nm/15nm   
 
2,02 x10-06 1,01  
  
 
4,53 x10-06 2,27  
I 
 
  
 
6,07 x10-06 3,04  
  
 
8,00 x10-06 4,00  
  
 
1,00 x10-05 5,01  
  
 
1,41 x10-05 7,04  
  
 
1,80 x10-05 9,01  
  
 
2,30 x10-05 11,52  
  
 
2,60 x10-05 13,01  
  
 
3,01 x10-05 15,04  
28.Feb / #17                   
  2,00 x10-06 0 0 







If (exc=295 nm)
 
 
 
 
 
 
 
 
15 
 
 
 
 
 
 
 
15 
 
 
 
 
 
 
 
24,2 
 
 
 
 
 
 
 
4nm/15nm 
  
 
2,02 x10-06 1,01  
  
 
4,53 x10-06 2,27  
  
 
6,07 x10-06 3,04  
  
 
8,00 x10-06 4,00  
  
 
1,00 x10-05 5,01  
  
 
1,41 x10-05 7,04  
  
 
1,80 x10-05 9,01  
  
 
2,30 x10-05 11,52  
  
 
2,60 x10-05 13,01  
04.Mar / #18                   
  2,00 x10-06 0 0 
If (exc=295 nm)
 
15 15 28 4nm/15nm 
  
 
6,01 x10-06 3,00  
  
 
8,01 x10-06 4,01  
  
 
1,00 x10-05 5,01  
  
 
1,40 x10-05 7,01  
  
 
1,80 x10-05 9,01  
  
 
2,30 x10-05 11,52  
  
 
2,60 x10-05 13,02  
J 
 
  
 
3,00 x1005 15,00  
04.Mar / #19                   
  2,00 x10-06 0 0 

If (exc=295 nm)
 
 
 
37 
 
 
36,9 
 
 
23,4 
 
 
4nm/15nm 
  
 
2,00 x10-06 1,00  
  
 
2,43 x10-06 1,22  
  
 
4,01 x10-06 2,00  
  
 
4,82 x10-06 2,41  
  
 
6,01 x10-06 3,00  
  
 
8,01 x10-06 4,01  
  
 
1,00 x10-05 5,01  
  
 
1,20 x10-05 6,01  
  
 
1,40 x10-05 7,01  
  
 
1,60 x10-05 8,01  
  
 
1,80 x10-05 9,01  
  
 
2,00 x10-05 10,02  
  
 
2,40 x10-05 12,02  
  
 
2,80 x10-05 14,02  
  
 
3,20 x10-05 16,00  
  
 
3,60 x10-05 18,01  
                    
Table 2. Conditions of the experiments performed for the system HSA + RuC. (at different temperatures);  
 
 
 
 
 
 
 
 
K 
 
 Annex A3-Experiments with Warfarin (37 ºC) 
 
date / experiment CHSA / M Conc. WF/M Complex concs./M ratio If (exc= 310 nm) T incub /ºC 
T measure/ºC 
(bath) 
time incub. /h 
Emission slits/ 
time-resolved 
emission slits 
05.Dec / #20                   
WF alone 
 
0,00  
  
 37 37 
  
2 nm / 15 nm 
  
 
5,17 x10-07 
  
  
 
7,50 x10-07 
  
  
 
1,01 x10-06 
  
  
 
1,27 x10-06 
  
  
 
1,53 x10-06 
  
  
 
1,76 x10-06 
  
  
 
2,02 x10-06 
  
  
 
2,51 x10-06 
  
  
 
3,00 x10-06 
  
  
 
3,52 x10-06 
  
06.Dec / #21                   
WF+HSA 
2,00 x10-06 
0,00  
 
0,00 
 37 37 23,16 2 nm / 15 nm 
  5,17 x10-07 
 
0,25 
  7,50 x10-07 
 
0,38 
  1,01 x10-06 
 
0,50 
  1,27 x10-06 
 
0,63 
  1,50 x10-06 
 
0,75 
  1,76 x10-06 
 
0,88 
  2,02 x10-06 
 
1,00 
  2,51 x10-06 
 
1,25 
  3,00 x10-06 
 
1,50 
L 
 
  3,52 x10-06 
 
1,75 
13.Ded / #22                   
WF+HSA+RuC 
2,01 x10-06 2,00 x10-06 
0 0,00 
 37 37 24 2 nm / 15 nm 
  2,01 x10-06 1,01 
  4,03 x10-06 2,01 
  8,00 x10-06 4,00 
  1,40 x10-05 7,02 
  2,00 x10-05 10,02 
  2,80 x10-05 14,02 
  3,60 x10-05 18,02 
  4,40 x10-05 22,02 
21.Jan / #23                   
WF alone 
 
0 
  
 37 37 
 
2 nm / 15 nm 
  
 
4,98 x10-07 
  
  
 
7,47 x10-07 
  
  
 
9,96 x10-07 
  
  
 
1,24 x10-06 
  
  
 
1,49 x10-06 
  
  
 
1,74 x10-06 
  
  
 
1,99 x10-06 
  
  
 
2,49 x10-06 
  
  
 
3,01 x10-06 
  
  
 
3,51 x10-06 
  
  
 
5,00 x10-06 
  
  
 
1,00 x10-05 
  
  
 
1,20 x10-05 
  
  
 
1,50 x10-05 
  
  
 
1,80 x10-05 
  
M 
 
  
 
2,00 x10-05 
  
  
 
2,50 x10-05 
  
  
 
3,00 x10-05 
  
  
 
3,50 x10-05 
  
  
 
3,80 x10-05 
  
  
 
4,00 x10-05 
  
22.Jan / #24                   
WF+HSA 
2,00 x10-06 
0,00  
 
0 
 37 37 23 2 nm / 11 nm 
  4,98 x10-07 
 
0,25 
  7,47 x10-07 
 
0,37 
  9,96 x10-07 
 
0,50 
  1,24 x10-06 
 
0,62 
  1,49 x10-06 
 
0,75 
  1,74 x10-06 
 
0,87 
  1,99 x10-06 
 
0,99 
  2,49 x10-06 
 
1,24 
  3,01 x10-06 
 
1,50 
  3,51 x10-06 
 
1,75 
  1,00 x10-05 
 
5,00 
  1,20 x10-05 
 
5,99 
  1,50 x10-05 
 
7,50 
  2,00 x10-05 
 
9,99 
  2,50 x10-05 
 
12,49 
  3,00 x10-05 
 
14,99 
  3,30 x10-05 
 
16,48 
  3,50 x10-05 
 
17,49 
  4,00 x10-05 
 
19,99 
20.Jan / #25                   
N 
 
WF+HSA+RuC 
2,00 x10-06 1,99 x10-06 
0 0,00 





 
 
 
37 
 
 
 
37 
 
 
 
24 
 
 
 
2 nm / 15 nm 
  2,03 x10-06 1,02 
  4,00 x10-06 2,01 
  8,00 x10-06 4,02 
  1,40 x10-05 7,05 
  2,00 x10-05 10,05 
  2,80 x10-05 14,07 
  3,60 x10-05 18,09 
  4,40 x10-05 22,11 
20.Feb / #26                   
WF alone 
 
0,0 
  
 37 37 
 
3 nm / 15 nm 
  
 
1,01 x10-06 
  
  
 
2,00 x10-06 
  
  
 
3,01 x10-06 
  
  
 
5,00 x10-06 
  
  
 
1,00 x10-05 
  
  
 
1,40 x10-05 
  
  
 
1,50 x10-05 
  
  
 
1,80 x10-05 
  
  
 
2,00 x10-05 
  
  
 
2,30 x10-05 
  
  
 
2,50 x10-05 
  
  
 
2,80 x10-05 
  
  
 
3,00 x10-05 
  
  
 
3,30 x10-05 
  
  
 
3,50 x10-05 
  
  
 
3,80 x10-05 
  
  
 
4,00 x10-05 
  
O 
 
  
 
6,00 x10-05 
  
  
 
8,00 x10-05 
  
21.Feb / #27                   
WF+HSA 
2,00 x10-06 
0,00 x10-06 
 
0,00 
 37 37 1 2,5nm/ 11nm 
  5,04 x10-07 
 
0,25 
  1,01 x10-06 
 
0,50 
  1,49 x10-06 
 
0,75 
  1,76 x10-06 
 
0,88 
  2,00 x10-06 
 
1,00 
  2,50 x10-06 
 
1,25 
  5,00 x10-06 
 
2,50 
  1,00 x10-05 
 
5,01 
  1,50 x10-05 
 
7,50 
  2,00 x10-05 
 
10,00 
  2,50 x10-05 
 
12,50 
  3,00 x10-05 
 
15,01 
  3,50 x10-05 
 
17,51 
  4,00 x10-05 
 
20,01 
20.Feb / #28                   
WF+HSA+RuC 
2,00 x10-06 2,00 x10-06 
0 0,00 
 37 37 25 3 nm / 15 nm 
  2,01 x10-06 1,01 
  4,02 x10-06 2,01 
  7,97 x10-06 3,99 
  1,40 x10-05 7,01 
  2,00 x10-05 10,02 
  2,80 x10-05 14,01 
  3,60 x10-05 18,03 
  4,40 x10-05 22,03 
P 
 
25.Feb / #29                   
WF+HSA+RuC 
2,01 x10-06 2,02 x10-06 
0 0,00 




 
 
 
37 
 
 
 
37 
 
 
 
26,5 
 
 
 
3 nm / 15 nm 
  2,05 x10-06 1,02 
  4,10 x10-06 2,03 
  8,05 x10-06 3,99 
  1,41 x10-05 6,96 
  2,01 x10-05 9,94 
  2,80 x10-05 13,86 
  3,60 x10-05 17,85 
  4,41 x10-05 21,84 
                    
Table 1. Conditions for the experiments involving the site marker Warfarin. There are three systems Warfarin alone solutions, Warfarin-HSA solutions (keeping the protein constant and increasing the 
concentration of the site marker) and Warfarin-HSA-RuC solutions (keeping the protein and site marker equimolar and increasing the concentration of the complex). 
 
 
 
 
Figure A. Emission spectra of the system WF-RuC recorded from samples of constant concentration of Warfarin with increasing concentrations of RuC (darker 
shade CRuC=2 μM, lighter shade CRuC= 44 μM) Experiments incubated and measured at 37ºC in 10 mM HEPES (pH 7,4). The red discontinuous line is Warfarin with a 
concentration of 2 μM. 
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Figure B. Overlapping spectra: absorption spectrum of the complex and the emission spectrum of the site marker Warfarin in 10 mM HEPES pH 7,4. 
 
 A4. Experiments with Dansylglycine (37 ºC) 
 
date / experiment CHSA / M Conc. DG/M 
Complex 
concs./M 
ratio If (exc= 335 nm) T incub/ºC T measure/ºC (bath) time incub. /h 
Emission slits/ 
time-resolved 
emission slits 
10.Dec / #30                   
DG alone 
 
0,00 
  
 37 36,9 24 2 nm / 15 nm 
  
 
2,00 x10-06 
  
  
 
5,01 x10-06 
  
  
 
8,02 x10-06 
  
  
 
1,00 x10-05 
  
  
 
1,20 x10-05 
  
  
 
1,40 x10-05 
  
  
 
1,50 x10-05 
  
  
 
1,80 x10-05 
  
  
 
2,00 x10-05 
  
0
0,2
0,4
0,6
0,8
1
250 300 350 400 450 500
If
 o
r 
 a
b
so
rp
ti
o
n
 (
a
.u
.)
 
Wavelength (nm) 
WF alone 
RuC absorption 
spectrum 
R 
 
  
 
2,30 x10-05 
  
  
 
2,50 x10-05 
  
  
 
2,80 x10-05 
  
  
 
3,00 x10-05 
  
  
 
3,30 x10-05 
  
  
 
3,50 x10-05 
  
  
 
3,80 x10-05 
  
  
 
4,00 x10-05 
  
11.Dec / #31                   
DG+HSA 
2,00 x10-06 
0,00  
 
0,00 


 
37 
 
36,9 
 
23,16 
 
2 nm / 15 nm 
  2,00 x10-06 
 
1,00 
  5,01 x10-06 
 
2,51 
  8,02 x10-06 
 
4,01 
  1,00 x10-05 
 
5,01 
  1,50 x10-05 
 
7,51 
  2,00 x10-05 
 
10,01 
  2,50 x10-05 
 
12,50 
  3,00 x10-05 
 
15,01 
  3,50 x10-05 
 
17,50 
  4,00 x10-05 
 
20,01 
16.Ded / #32                   
DG+HSA+RuC 
2,00 x10-06 2,00 x10-06 
0 0,00 
 37 36,9 24 2 nm / 15 nm 
  2,05 x10-06 1,03 
  4,04 x10-06 2,02 
  8,02 x10-06 4,02 
  1,41 x10-05 7,03 
  2,00 x10-05 10,02 
  2,80 x10-05 14,04 
S 
 
  3,60 x10-05 18,03 
  4,40 x10-05 22,04 
15.Jan / #33                   
DG alone 
 
0 
  
 37 36,9 24 2 nm / 15 nm 
  
 
2,02 x10-06 
  
  
 
5,02 x10-06 
  
  
 
8,01 x10-06 
  
  
 
1,00 x10-05 
  
  
 
1,20 x10-05 
  
  
 
1,40 x10-05 
  
  
 
1,50 x10-05 
  
  
 
1,80 x10-05 
  
  
 
2,00 x10-05 
  
  
 
2,30 x10-05 
  
  
 
2,50 x10-05 
  
  
 
2,80 x10-05 
  
  
 
3,00 x10-05 
  
  
 
3,30 x10-05 
  
  
 
3,50 x10-05 
  
  
 
3,80 x10-05 
  
  
 
4,00 x10-05 
  
16.Jan / #34                   
DG+HSA 
2,01 x10-06 
0,00  
 
0 
 37 36,9 23 2 nm / 15 nm 
  2,55 x10-07 
 
0,13 
  5,10 x10-07 
 
0,25 
  7,44 x10-07 
 
0,37 
  9,99 x10-07 
 
0,50 
  1,51 x10-06 
 
0,75 
T 
 
  1,74 x10-06 
 
0,87 
  2,00 x10-06 
 
0,99 
  2,51 x10-06 
 
1,25 
  4,99 x10-06 
 
2,49 
  7,99 x10-06 
 
3,98 
  1,00 x10-05 
 
4,98 
  1,50 x10-05 
 
7,47 
  2,00 x10-05 
 
9,95 
  2,50 x10-05 
 
12,44 
  3,00 x10-05 
 
14,93 
  3,50 x10-05 
 
17,42 
  4,00 x10-05 
 
19,90 
14.Jan / #35                   
DG+HSA+RuC 
 
 
2,00 x10-06 
 
 
2,00 x10-06 
0 0,00 



 
 
37 
 
 
36,9 
 
 
24 
 
 
2 nm / 15 nm 
  2,04 x10-06 1,02 
  4,02 x10-06 2,01 
  8,03 x10-06 4,02 
  1,40 x10-05 7,02 
  2,00 x10-05 10,02 
  2,80 x10-05 14,02 
  3,60 x10-05 18,04 
20.Feb / #36                   
DG alone 
 
0 
  
 37 36,9 23 4 nm / 15 nm 
  
 
1,00 x10-06 
  
  
 
2,00 x10-06 
  
  
 
3,00 x10-06 
  
  
 
5,00 x10-06 
  
  
 
1,00 x10-05 
  
U 
 
  
 
1,20 x10-05 
  
  
 
1,50 x10-05 
  
  
 
1,80 x10-05 
  
  
 
2,00 x10-05 
  
  
 
2,30 x10-05 
  
  
 
2,50 x10-05 
  
  
 
2,80 x10-05 
  
  
 
3,00 x10-05 
  
  
 
3,30 x10-05 
  
  
 
3,50 x10-05 
  
  
 
3,80 x10-05 
  
  
 
4,00 x10-05 
  
21.Feb / #37                   
DG+HSA 
 
2,00 x10-06 
0 
 
0,00 



 
37 
 
36,9 
 
24 
 
2,5 nm/ 12nm 
  5,00 x10-07 
 
0,25 
  1,00 x10-06 
 
0,50 
  1,50 x10-06 
 
0,75 
  1,74 x10-06 
 
0,87 
  2,00 x10-06 
 
1,00 
  3,00 x10-06 
 
1,50 
  5,00 x10-06 
 
2,50 
  1,00 x10-05 
 
5,00 
  1,50 x10-05 
 
7,51 
  2,00 x10-05 
 
10,01 
  2,50 x10-05 
 
12,51 
  3,00 x10-05 
 
15,01 
  3,50 x10-05 
 
17,51 
  4,02 x10-05 
 
20,11 
V 
 
20.Feb / #38                   
DG+HSA+RuC 
2,00 x10-06 2,00 x10-06 
0 0,00 
 37 37 22 3 nm / 15 nm 
  2,02 x10-06 1,01 
  3,99 x10-06 2,00 
  8,03 x10-06 4,02 
  1,40 x10-05 7,00 
  2,00 x10-05 10,01 
  2,80 x10-05 14,03 
  3,60 x10-05 18,03 
  4,40 x10-05 22,05 
25.Feb / #39                   
DG+HSA+RuC 
2,01 x10-06 2,00 x10-06 
0 0,00 
 37 37 24,5 3 nm / 15 nm 
  2,05 x10-06 1,02 
  4,10 x10-06 2,05 
  8,05 x10-06 4,02 
  1,41 x10-05 7,02 
  2,01 x10-05 10,02 
  2,80 x10-05 13,97 
  3,60 x10-05 18,00 
  4,41 x10-05 22,02 
                    
Table 1. Conditions of the experiments involving the site marker Dansylglycine. There are three systems Dansylglycine alone solutions, Dansylglycine-HSA solutions (keeping the protein constant and 
increasing the concentration of the site marker) and Dansylglycine-HSA-RuC solutions (keeping the protein and site marker equimolar and increasing the concentration of the complex). 
 
 
 
 
 
 
 
W 
 
ANNEX B. STERN-VOLMER ANALYSIS 
 
The equations and constants obtained from the Stern-Volmer analysis are shown in the following table: 
       
average data 
 
T(ºC)/CHSA 
(µM) Slits 
(KD±SD) / M
-1 
x(10
4
) 
(KS ±SD) / M
-1 
x(10
4
) equations R
2
 
(KD±SD)/M
-1 
x(10
4
) 
(KS±SD)/M
-1 
x(10
4
) R
2 
(0 / If0) 
#1 RT / 5,12 2 nm (1,30 ± 0,06) (2,63 ± 0,52) 
0/=(1,02 ± 0,02) + (1,30 ± 0,06) x 10
4 Cq 0,991 
N/A N/A N/A 
If0/If= (1,04 ± 0,06) + (1,10 ± 0,50) x 10
4Cq + (3,42 ± 0,66) x 108 Cq2 0,996 
#2 36,9/2,24 2 nm N/A N/A 
0/= (1,04 ± 0,05) + (5,61 ± 1,11) x 10
4
 Cq * 0,927 
N/A N/A N/A 
If0/If= (1,01 ± 0,01) + (3,51 ± 0,63) x 10
4 Cq+ (2,45 ± 0,63) x 109 Cq2 0,996 
#3 RT / 2,51 2 nm (2,59 ± 0,11) (1,31 ± 0,65) 
0/= (0,982 ± 0,008) + (2,6 ± 0,1) x 10
4 Cq 0,987 
(5,58±0,17) (3,23±0,32) 0,995/0,997 
If0/If= (1,01 ± 0,02) + (3,91 ± 0,64) x 10
4
 Cq+ (5,64 ± 4,92) x 10
8
Cq
2
 0,993 
#4 RT / 2,50 2 nm (2,57 ± 0,14) (2,24 ± 0,85) 
0/= (0,99 ± 0,02) + (2,57 ± 0,14) x 10
4Cq 0,985 
If0/If= (0,98 ± 0,03) + (5,37 ± 0,55) x 10
4 Cq + (5,74 ± 2,15) x 108 Cq2 0,996 
#5 RT / 2,51 2 nm (4,89 ± 0,17) (4,83 ± 0,80) 
0/= (0,99 ±  0,02) + (4,90 ± 0,17) x 10
4
Cq 0,993 
If0/If= (1,06 ± 0,05) + (2,33 ± 0,96) x 10
4 Cq + (2,36 ± 0,38) x 109 Cq2 0,994 
#6 36,9 / 2,50 2 nm (6,08 ± 0,19) (2,01 ± 0,39) 
0/= (0,96 ± 0,03) + (6,08 ± 0,19) x 10
4 Cq 0,996 
If/If= (0,98 ± 0,03) + (5,76 ± 0,62) x 10
4
 Cq + (1,23± 0,23) x 10
9
 Cq
2
 0,999 
#7 36,9 / 2,00 2 nm (4,12 ± 0,14) (2,41 ± 0,41) 
0/= (0,98 ± 0,03) + (4,12 ± 0,14) x 10
4Cq 0,995 
(4,29±0,10) (2,84±0,21) 0,993/0,998 
If0/If= (0,98 ± 0,03) + (6,53 ± 0,39) x 10
4 Cq + (1,04 ± 0,09) x 109 Cq2 0,999 
#8 36,9 / 2,00 2 nm (5,12 ± 0,18) (2,28 ± 0,18) 
0/= (1,11 ± 0,03) + (5,12 ± 0,18) x 10^4 Cq 0,99 
If0/If= (0,97 ± 0,02) + (6,20 ± 0,33) x 10
4 Cq + (1,17 ± 0,08) x 109 Cq2 0,999 
#9 RT / 2,00 2 nm (4,56 ± 0,21) (2,24 ± 1,30) 
0/= (1,02 ± 0,01) + (4,56 ± 0,21) x 10
4 Cq 0,981 
If0/If= (1,01 ± 0,02) + (5,47 ± 0,70) x 10
4 Cq + (1,02 ± 0,59) x 109 Cq2 0,99 
#10 25 / 2,00 2 nm (1,5 ± 0,13) (2,68 ± 0,36) 0/= (1,00 ± 0,03) + (1,53 ± 0,13) x 10
4 Cq 0,979 N/A N/A N/A 
X 
 
If0/If= (1,01 ± 0,02) + (4,21 ± 0,33) x 10
4 Cq + (0,91 ± 9,64) x 107 Cq2 0,998 
#11 25 / 2 4 nm (1,99 ± 0,07) (1,91 ± 0,51) 
0/= (1,01 ± 0,01) + (1,99 ± 0,07) x 10
4 Cq 0,995 
If0/If= (0,97 ± 0,04) + (3,91 ± 0,50) x 10
4Cq+ (1,86 ± 1,37) x 108 Cq2 0,994 
#12 36,9 / 2 4 nm (8,56 ± 0,33) (3,05 ± 0,26) 
0/= (0,92 ± 0,07) + (8,56 ± 0,33) x 10
4 Cq 0,991 
N/A N/A N/A 
If0/If= (0,95 ± 0,04) + (9,89 ± 0,70) x 10
4Cq+ (2,61 ± 0,20) x 109 Cq2 0,999 
#19 36,9 / 2 4 nm (3,90 ± 0,12) (2,44 ± 0,37) 
0/= (0,93 ± 0,02) + (3,90 ± 0,12) x 10
4 Cq 0,991 
If0/If= (0,99 ± 0,03) + (4,27 ± 0,51) x 10
4 Cq + (9,51 ± 1,42) x 108Cq2 0,996 
#13 20 / 2 4 nm (2,93 ± 0,09) (3,12 ± 0,43) 
0/= (1,02 ± 0,01) + (2,93 ± 0,09) x 10
4 Cq 0,994 
(2,41±0,11) (1,05±0,44) 0,981/0,995 
If0/If= (0,95 ± 0,03) + (6,05 ± 0,42) x 10
4
 Cq+ (-1,34 ± 1,17) x 10
8
 Cq
2
 0,997 
#15 20 / 2 4 nm (2,31 ±  0,21) (1,10 ±  0,69) 
0/= (1,08 ± 0,03) + (2,31 ± 0,21) x 10
4 Cq 0,952 
If0/If= (1,04 ± 0,03) + (2,99 ± 0,48) x 10
4 Cq + (2,55 ± 1,56) x 108 Cq2 0,994 
#16 30 / 2 4 nm (1,31 ± 0,19) (2,89 ± 0,64) 
0/= (1,06 ± 0,03) + (1,31 ± 0,19) x 10
4 Cq 0,907 
(1,57±0,12) (2,02±0,51) 0,975/0,994 
If0/If= (0,99 ± 0,03) + (4,20 ± 0,61) x 10
4
 Cq + (3,20 ± 1,98) x 10
8
 Cq
2
 0,996 
#14 30 / 2 4 nm (1,85 ± 0,14) (2,79 ± 0,71) 
0/= (1,03 ± 0,03) + (1,85 ± 0,14) x 10^4 Cq 0,977 
If0/If= (0,99 ± 0,02) + (2,80 ± 0,40) x 10
4 Cq + (5,17 ± 1,25) x 108  Cq2 0,997 
#17 15 / 2 4 nm (1,52 ± 0,09) *(0,39 ±0,18) 
0/= (1,01 ± 0,01) + (1,50 ± 0,09) x 10
4
 Cq 0,989 
(1,48±0,11) (7,65±0,98) 0,978/0,998 
If0/If= (1,01 ± 0,01) + (1,90 ± 0,16) x 10
4 Cq + (1,07 ± 0,61) x 108 Cq2 0,999 
#18 15 / 2 4 nm (4,10 ± 0,14) (2,16 ± 0,52) 
0/= (1,01 ± 0,02) + (4,10 ± 0,14) x 10
4 Cq 0,994 
If0/If= (1,03 ± 0,05) + (2,29 ± 0,69) x 10
4
 Cq + (8,87 ± 2,12) x 10
8
 Cq
2
 0,993 
Table 1. Static and dynamic quenching constants and Stern-Volmer equations for each experiment. The average constants are also displayed for the experiments that the calculation was 
relevant and reliable. (* The results obtained were not good enough for the calculation of reliable constants, N/A: non-applicable because the average could not be made due to difference in the 
slits or some experimental error, SD: standard deviation). 
 
 
 
 
 
Y 
 
ANNEX C. PSEQUAD: CALCULATION OF THE BINDING CONSTANTS 
        
average 
  
T(ºC)/CHSA (μM) slits log β ± SD  FP 
Minimum 
reached? 
log KD/ log KS log β ± SD FP 
#1 
HSA-RuC 
RT/5,12 2 nm 
log β1= 4,38 ± 0,01 201421 Yes 4,11 / 4,42 N/A N/A 
HSA-(RuC)2 log β2= 8,53 ± 0,07 
#2 
HSA-RuC 
36,9/2,24 2 nm 
log β1= 4,72 ± 0,01 97331 Yes N/A N/A N/A 
HSA-(RuC)2 N/A (rejected) 
#3 
HSA-RuC 
RT/2,51 2 nm 
log β1= 4,67 ± 0,01 118464 Yes 4,41 / 4,12 
log β1= 4,72 ± 0,01          
log β2= 9,00 ± 0,07* 
129028 
HSA-(RuC)2 N/A (rejected) 
#4 
HSA-RuC 
RT/2,50 2 nm 
log β1= 4,74 ± 0,01 111955 Yes 4,41 / 4,35 
HSA-(RuC)2 log β2= 9,45 ± 0,02 
#5 
HSA-RuC 
RT/2,51 2 nm 
log β1= 4,71 ± 0,01 159116 Yes 4,41 / 4,35 
HSA-(RuC)2 N/A (rejected) 
#6 
HSA-RuC 
36,9/2,50 2 nm 
log β1= 4,76 ± 0,01 179361 Yes 4,78 / 4,30 
HSA-(RuC)2 N/A (rejected) 
#7 
HSA-RuC 
36,9/2,00 2 nm 
log β1= 4,81 ± 0,01 120189 Yes 4,61 / 4,38 
log β1= 4,78 ± 0,01          
log β2= 9,52 ± 0,01 
116410 
HSA-(RuC)2 log β2= 9,34 ± 0,02 
#8 
HSA-RuC 
36,9/2,00 2 nm 
log β1= 4,776 ± 0,005 88796 Yes 4,71 / 4,36 
HSA-(RuC)2 log β2= 9,402 ± 0,012 
#9 
HSA-RuC 
RT/2,00 2 nm 
log β1= 4,90 ± 0,01 116386 Yes 4,66 / 4,35 
HSA-(RuC)2 log β2= 10,24 ± 0,02 
#10 
HSA-RuC 
25/2,00 2 nm 
log β1= 4,57 ± 0,01 180999 Yes 4,18 / 4,43 N/A N/A 
HSA-(RuC)2 N/A (rejected) 
Z 
 
#11 
HSA-RuC 
25/2,00 4 nm 
log β1= 4,52 ± 0,01 671146 Yes 4,30 / 4,28 
HSA-(RuC)2 log β2= 9,06 ± 0,09 
#12 
HSA-RuC 
37/2,00 4 nm 
log β1= 4,93 ± 0,01 669517 Yes 4,93 / 4,48 
N/A N/A 
HSA-(RuC)2 log β2= 9,74 ± 0,02 
#19 
HSA-RuC 
37/2,00 4 nm 
log β1= 4,42 ± 0,01 436652 Yes 4,59 / 4,39 
HSA-(RuC)2 log β2= 9,57 ± 0,01 
#13 
HSA-RuC 
20/2,00 4 nm 
log β1= 4,73 ± 0,01 659153 Yes 4,47 / 4,49 
log β1= 4,70 ± 0,01          
log β2= 8,73 ± 0,11 
534363 
HSA-(RuC)2 log β2= 9,31 ± 0,03 
#15 
HSA-RuC 
20/2,00 4 nm 
log β1= 4,61 ± 0,01 601801 Yes 4,36 / 4,04 
HSA-(RuC)2 N/A (rejected) 
#14 
HSA-RuC 
30/2,00 4 nm 
log β1= 4,53 ± 0,01 478050 Yes 4,27 / 4,45 
log β1= 4,59 ± 0,01          
log β2= 9,32 ± 0,04 
519463 
HSA-(RuC)2 log β2= 8,99 ± 0,05 
#16 
HSA-RuC 
30/2,00 4 nm 
log β1= 4,70 ± 0,01 609249 Yes 4,12 / 4,46 
HSA-(RuC)2 log β2= 9,27 ± 0,04 
#17 
HSA-RuC 
15/2,00 4 nm 
log β1= 4,40 ± 0,01 286363 Yes 4,18 / 3,59 
log β1= 3,94 ± 0,06          
log β2= 9,39 ± 0,03 
933484 
HSA-(RuC)2 N/A (rejected) 
#18 
HSA-RuC 
15/2,00 4 nm 
log β1= 4,51 ± 0,01 528916 Yes 4,61 / 4,33 
HSA-(RuC)2 N/A (rejected) 
Table 1. Global formation constants for the experiments involving the protein HSA and RuC at different concentrations, the temperature shown is the temperaalso varies for the 
different experiments. (FP stands for Fitting Parameter, * values taken from the average, not every individual experiment showed the formation of th e second species HSA-(RuC)2 ). 
The experiments performed at 25 ºC were executed with different slits and therefore their average was not determined. 
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ANNEX D. Time-resolved measurements 
 
date /        
experiment 
CHSA / M CComplex/M ratio  1  2  3 α1 α2 α3 χ2   bar < > 
time-
resolved 
STV 
Slits 
(nm) 
8.Oct /#1 
                            
 
5,12x10
-6 0,00 0,00 0,57 3,58 7,22 0,25 0,32 0,42 1,34 4,36 6,03 1,00 
8 
  
2,50x10-06 0,49 0,54 3,23 7,12 0,24 0,32 0,44 1,44 4,28 5,99 1,02 
  
5,01 x10-06 0,98 
          
  
1,25 x10-05 2,44 0,40 3,26 7,16 0,37 0,30 0,33 1,34 3,49 5,78 1,25 
 
* 2,51 x10-05 4,90 0,50 3,14 7,11 0,41 0,30 0,29 1,29 3,23 5,54 1,35 
 
* 5,01 x10-05 9,79 0,46 2,73 6,92 0,48 0,29 0,22 1,21 2,58 5,06 1,69 
 
* 7,51 x10-05 14,68 0,46 2,58 6,77 0,53 0,29 0,18 1,19 2,20 4,64 1,98 
22.Oct / #2                             
 
2,24 x10-06 0,00  0 0,55 3,05 6,98 0,26 0,29 0,45 1,15 4,15 5,91 1,00 
15 
  
1,30 x10-06 0,58 
          
  
2,50 x10-06 1,11 0,32 2,88 6,93 0,38 0,26 0,36 1,18 3,38 5,79 1,23 
  
3,81 x10-06 1,69 
          
  
5,00 x10-06 2,22 0,29 2,70 6,87 0,43 0,25 0,33 1,29 3,03 5,69 1,37 
  
6,29 x10-06 2,79 
          
  
7,50 x10-06 3,33 0,26 2,58 6,90 0,43 0,26 0,31 1,34 2,92 5,67 1,42 
  
8,74 x10-06 3,88 
          
  
9,99 x10-06 4,43 0,41 2,77 6,92 0,39 0,29 0,32 1,21 3,18 5,54 1,31 
25.Oct / #3 
   
          
  
 
2,51 x10-06 0,00  0,00 0,70 3,81 7,28 0,30 0,28 0,42 1,49 4,31 6,09 1,00 10 
BB 
 
  
1,30 x10-06 0,52 
          
  
2,50 x10-06 1,00 0,65 3,51 7,31 0,38 0,29 0,33 1,64 3,66 5,80 1,05 
  
3,80 x10-06 1,51 0,53 3,26 7,29 0,42 0,28 0,30 1,50 3,30 5,70 1,07 
  
4,39 x10-06 1,75 0,40 2,79 7,11 0,44 0,27 0,28 1,33 2,97 5,60 1,09 
  
6,30 x10-06 2,51 0,66 3,05 7,20 0,43 0,31 0,26 1,48 3,09 5,32 1,14 
  
7,50 x10-06 2,99 0,60 2,84 7,15 0,44 0,31 0,25 1,33 2,92 5,25 1,16 
  
8,77 x10-06 3,49 0,35 2,41 6,92 0,49 0,30 0,21 1,26 2,33 5,03 1,21 
  
1,01 x10-05 4,00 0,48 2,58 7,08 0,48 0,33 0,19 1,23 2,43 4,85 1,25 
  
1,25 x10-05 4,99 0,43 2,40 6,97 0,50 0,34 0,17 1,16 2,18 4,63 1,31 
29-Oct / #4 
             
  
 
2,50 x10-06 0,00  0,00 0,31 3,25 7,15 0,40 0,22 0,37 1,36 3,53 6,11 1,00 
14 
  
2,51 x10-06 1,00 0,43 3,55 7,31 0,42 0,26 0,32 1,56 3,43 5,92 1,03 
  
5,01 x10-12 0,00 0,38 3,05 7,14 0,44 0,24 0,32 1,52 3,17 5,85 1,11 
  
7,50 x10-06 3,00 0,53 3,35 7,30 0,43 0,28 0,29 1,74 3,27 5,69 1,08 
  
1,00 x10-05 4,01 0,36 2,94 7,17 0,51 0,25 0,24 1,53 2,65 5,53 1,33 
  
1,25 x10-05 5,02 0,34 2,86 7,11 0,54 0,24 0,22 1,42 2,44 5,40 1,45 
  
 
1,50 x10-05 6,02 0,44 3,01 7,21 0,52 0,26 0,21 1,33 2,56 5,30 1,38 
  
 
1,76 x10-05 7,02 0,46 2,89 7,11 0,53 0,26 0,20 1,46 2,44 5,12 1,45 
  
 
2,01 x10-05 8,02 0,45 2,79 7,08 0,56 0,26 0,18 1,34 2,27 4,98 1,56 
  
 
2,51 x10-05 10,03 0,51 2,89 7,08 0,57 0,26 0,17 1,60 2,23 4,80 1,59 
01.Nov / #5 
             
  
 
2,51 x10-06 0,00  0,00 0,44 3,32 7,24 0,31 0,26 0,43 1,17 4,12 6,21 1,00 
13 
  
2,50 x10-06 1,00 0,48 3,05 7,21 0,35 0,29 0,36 1,18 3,64 5,88 1,13 
  
5,00 x10-06 1,99 0,53 3,44 7,37 0,40 0,29 0,32 1,14 3,54 5,87 1,17 
  
7,50 x10-06 2,99 0,23 2,60 7,10 0,53 0,22 0,25 1,31 2,47 5,70 1,67 
  
9,97 x10-06 3,97 0,24 2,61 7,10 0,56 0,23 0,22 1,21 2,25 5,52 1,83 
  
1,25 x10-05 4,98 0,28 2,64 7,11 0,51 0,24 0,24 1,30 2,52 5,58 1,64 
  
1,50 x10-05 5,98 0,32 2,67 7,08 0,53 0,25 0,22 1,25 2,39 5,37 1,73 
CC 
 
  
1,75 x10-05 6,99 0,36 2,63 7,05 0,55 0,26 0,19 1,23 2,22 5,10 1,86 
  
1,99 x10-05 7,94 0,33 2,43 6,93 0,56 0,26 0,18 1,14 2,06 4,98 2,00 
  
2,50 x10-05 9,96 0,35 2,32 6,82 0,58 0,26 0,16 1,21 1,90 4,71 2,17 
5.Nov / #6 
             
  
 
2,50 x10-06 0,00  0 0,85 3,89 7,09 0,26 0,32 0,42 1,25 4,43 5,88 1,00 
14 
  
2,50 x10-06 1,00 0,85 3,74 6,99 0,32 0,32 0,36 1,39 3,99 5,59 1,11 
  
4,99 x10-06 2,00 0,59 3,22 6,89 0,39 0,30 0,31 1,47 3,34 5,39 1,33 
  
7,52 x10-06 3,01 0,71 3,28 6,88 0,43 0,29 0,28 1,65 3,18 5,20 1,39 
  
1,00 x10-05 4,00 0,76 3,21 6,94 0,44 0,30 0,27 1,51 3,13 5,15 1,41 
  
1,26 x10-05 5,02 0,79 3,28 6,98 0,45 0,30 0,25 1,62 3,08 5,09 1,44 
  
1,50 x10-05 6,01 0,32 2,25 6,58 0,49 0,29 0,22 1,42 2,25 4,89 1,97 
  
1,75 x10-05 7,01 0,40 2,30 6,55 0,50 0,30 0,20 1,39 2,21 4,66 2,01 
  
2,00 x10-05 8,00 0,85 2,98 6,78 0,53 0,29 0,18 1,48 2,55 4,46 1,74 
  
2,25 x10-05 9,00 0,47 2,43 6,57 0,56 0,29 0,15 1,26 1,93 4,23 2,29 
  
2,50 x10-05 9,99 0,39 2,11 6,39 0,56 0,30 0,14 1,33 1,74 4,09 2,55 
7.Nov / #7                             
  2,00 x10-06 0,00  0,00 0,67 3,45 6,79 0,28 0,30 0,43 1,24 4,10 5,68 1,00 
15 
  
 
2,00 x10-06 1,00 0,53 3,17 6,88 0,31 0,30 0,39 1,60 3,79 5,66 1,08 
  
 
2,40 x10-06 1,20 1,39 4,35 7,11 0,31 0,32 0,36 1,79 4,42 5,66 0,93 
  
 
4,01 x10-06 2,00 0,99 3,62 6,80 0,35 0,30 0,35 1,40 3,83 5,38 1,07 
  
 
4,81 x10-06 2,40 
            
 
6,00 x10-06 3,00 0,67 3,32 6,93 0,41 0,29 0,30 1,58 3,33 5,37 1,23 
  
 
8,00 x10-06 4,00 0,26 2,28 6,59 0,44 0,29 0,27 1,41 2,54 5,19 1,61 
  
 
1,00 x10-05 5,00 
            
 
1,20 x10-05 6,00 0,28 2,25 6,58 0,46 0,29 0,24 1,23 2,38 5,03 1,72 
  
 
1,40 x10-05 7,00 0,45 2,53 6,66 0,45 0,31 0,24 1,30 2,58 4,93 1,59 
  
 
1,60 x10-05 7,99 1,09 3,71 7,00 0,53 0,28 0,19 1,61 2,96 4,70 1,39 
  
 
1,80 x10-05 8,99 
          
DD 
 
  
 
2,00 x10-05 9,99 
            
 
2,40 x10-05 11,99 
            
 
2,80 x10-05 13,99 0,00 1,37 5,87 0,88 0,09 0,03 2,20 0,32 4,17 12,92 
  
 
3,20 x10-05 15,99 0,87 2,95 6,51 0,66 0,23 0,11 1,85 1,96 3,61 2,10 
  
 
3,60 x10-05 17,99 0,77 2,78 6,48 0,69 0,23 0,09 1,47 1,72 3,39 2,38 
  
 
4,00 x10-05 19,99 
            
 
4,41 x10-05 22,03 0,60 2,25 5,99 0,68 0,23 0,09 1,26 1,44 3,12 2,85 
  
 
4,80 x10-05 23,98 0,45 1,97 5,79 0,69 0,23 0,08 1,27 1,22 2,98 3,36 
12.Nov / #8                             
  2,00 x10-06 0,00  0,00 0,79 4,05 7,37 0,29 0,32 0,39 1,31 4,41 6,06 1,00 
15 
    2,00 x10-06 1,00 0,28 2,94 6,91 0,44 0,24 0,32 1,30 3,04 5,72 1,45 
    2,40 x10-06 1,20 0,37 3,18 7,03 0,41 0,26 0,33 1,19 3,29 5,75 1,34 
    4,01 x10-06 2,00 0,46 2,98 6,91 0,37 0,29 0,34 1,22 3,40 5,60 1,30 
    4,79 x10-06 2,40 0,42 2,93 6,89 0,42 0,27 0,31 1,13 3,11 5,50 1,42 
    6,00 x10-06 3,00 0,41 2,87 6,89 0,43 0,28 0,29 1,18 2,97 5,40 1,49 
    8,00 x10-06 4,00 0,43 2,74 6,82 0,44 0,28 0,28 1,15 2,85 5,30 1,55 
    1,00 x10-05 5,00 0,40 2,54 6,71 0,47 0,30 0,24 1,25 2,53 5,00 1,75 
    1,20 x10-05 6,02 0,43 2,47 6,73 0,48 0,30 0,22 1,21 2,44 4,91 1,81 
    1,40 x10-05 6,99 0,52 2,70 6,76 0,52 0,28 0,20 1,20 2,40 4,79 1,84 
    1,61 x10-05 8,03 0,46 2,40 6,61 0,52 0,29 0,20 1,21 2,23 4,64 1,98 
    1,80 x10-05 8,99 0,44 2,41 6,61 0,52 0,29 0,19 1,20 2,20 4,63 2,01 
    2,01 x10-05 10,04 0,47 2,48 6,65 0,56 0,28 0,16 1,05 2,04 4,43 2,16 
    2,40 x10-05 12,01 0,46 2,29 6,47 0,60 0,27 0,12 1,26 1,71 3,97 2,58 
    2,80 x10-05 14,01 0,56 2,44 6,53 0,61 0,27 0,12 1,29 1,77 3,85 2,49 
    3,20 x10-05 16,02 0,55 2,36 6,46 0,61 0,27 0,12 1,21 1,72 3,14 2,56 
    3,60 x10-05 17,99 0,52 2,29 6,33 0,65 0,25 0,09 1,29 1,51 3,48 2,92 
    4,00 x10-05 20,00 0,42 1,94 6,06 0,66 0,26 0,08 1,21 1,25 3,14 3,53 
    4,40 x10-05 22,00 0,44 2,11 6,07 0,70 0,23 0,07 1,27 1,24 3,14 3,55 
EE 
 
    4,80 x10-05 24,01 0,39 1,87 5,64 0,75 0,20 0,05 1,20 0,95 2,51 4,66 
15.Nov / #9                             
  2,00 x10-06 0,00  0,00 0,65 3,77 7,44 0,25 0,30 0,45 1,26 4,63 6,29 1,00 
15 
  * 2,00 x10-06 1,00 0,78 3,72 7,47 0,27 0,31 0,42 1,33 4,48 6,18 1,03 
    2,50 x10-06 1,25 0,99 4,00 7,63 0,31 0,34 0,35 1,37 4,34 6,01 1,07 
    3,01 x10-06 1,50 1,24 3,90 7,45 0,36 0,31 0,33 1,39 4,10 5,72 1,13 
    3,50 x10-06 1,75                   1,10 
    4,00 x10-06 2,00                   1,07 
    4,51 x10-06 2,26                   1,48 
    5,01 x10-06 2,50                   1,45 
    5,50 x10-06 2,75                   1,44 
    6,00 x10-06 3,00 1,08 3,61 7,50 0,41 0,33 0,26 1,43 3,60 5,43 1,29 
    6,51 x10-06 3,26                   1,39 
    7,01 x10-06 3,50                   1,64 
    7,51 x10-06 3,75 1,14 3,55 7,45 0,42 0,32 0,27 1,47 3,58 5,39 1,29 
    8,05 x10-06 4,02                   1,30 
    8,50 x10-06 4,25                   1,48 
  * 9,02 x10-06 4,51                   1,29 
  * 9,55 x10-06 4,78 0,97 3,46 7,45 0,45 0,32 0,24 1,32 3,28 5,26 1,41 
  * 1,00 x10-05 5,00 0,89 3,07 7,30 0,45 0,32 0,23 1,35 3,06 5,10 1,51 
  * 1,05 x10-05 5,26 0,87 2,97 7,17 0,44 0,32 0,24 1,25 3,05 5,07 1,52 
  * 1,11 x10-05 5,53 0,89 3,03 7,28 0,48 0,33 0,19 1,42 2,80 4,79 1,65 
31.Jan/ #12                             
  2,00 x10-06 0,00 x10+00 0,00 0,45 3,25 6,85 0,36 0,29 0,35 1,39 3,48 5,57 1,00 
15 
    1,99 x10-06 0,99 0,44 2,89 6,67 0,39 0,29 0,32 1,31 3,13 5,31 1,11 
    4,52 x10-06 2,26 0,47 2,66 6,62 0,41 0,32 0,27 1,24 2,82 5,02 1,24 
    6,05 x10-06 3,03 0,52 2,65 6,56 0,43 0,31 0,26 1,53 2,75 4,89 1,27 
    8,04 x10-06 4,02 2,43 0,53 6,45 0,33 0,49 0,19 1,52 2,25 4,35 1,55 
FF 
 
    1,00 x10-05 5,01 0,34 2,27 6,34 0,59 0,28 0,13 1,75 1,67 4,08 2,09 
    1,40 x10-05 7,00 0,38 2,08 6,10 0,62 0,29 0,10 1,62 1,41 3,46 2,47 
    1,81 x10-05 9,03 0,37 2,00 5,96 0,63 0,28 0,09 1,56 1,32 3,30 2,64 
    2,30 x10-05 11,52 0,50 2,17 6,07 0,67 0,27 0,06 1,45 1,29 2,86 2,70 
    2,60 x10-05 13,01 0,35 1,82 5,54 0,72 0,24 0,04 1,46 0,91 2,34 3,83 
    3,00 x10-05 15,00 0,39 1,88 5,54 0,71 0,24 0,05 1,59 0,99 2,43 3,51 
    3,51 x10-05 17,53 0,39 1,82 5,42 0,74 0,22 0,03 1,44 0,88 2,07 3,97 
04.Mar/ #19                             
  2,00 x10-06 0,00  0,00 0,65 3,09 6,52 0,31 0,32 0,37 1,63 3,59 5,24 1,00 
15 
    2,00 x10-06 1,00 0,67 2,99 6,41 0,35 0,32 0,33 1,74 3,30 5,01   
    2,43 x10-06 1,22 0,70 2,96 6,49 0,34 0,32 0,35 1,69 3,43 5,12 1,05 
    4,01 x10-06 2,00 0,81 3,26 6,53 0,39 0,31 0,30 1,47 3,30 4,97 1,09 
    4,82 x10-06 2,41 0,82 3,20 6,55 0,39 0,31 0,30 1,74 3,28 4,98 1,09 
    6,01 x10-06 3,00 0,72 3,03 6,49 0,39 0,32 0,29 1,42 3,11 4,88 1,15 
    8,01 x10-06 4,01 0,74 3,02 6,52 0,42 0,32 0,26 1,32 2,99 4,78 1,20 
    1,00 x10-05 5,01 0,70 2,70 6,40 0,43 0,33 0,24 1,42 2,72 4,57 1,32 
    1,20 x10-05 6,01 0,69 2,69 6,37 0,45 0,31 0,24 1,33 2,66 4,55 1,35 
    1,40 x10-05 7,01 0,71 2,76 6,47 0,48 0,33 0,20 1,29 2,51 4,37 1,43 
    1,60 x10-05 8,01 0,60 2,39 6,25 0,47 0,33 0,20 1,34 2,32 4,25 1,55 
    1,80 x10-05 9,01 0,68 2,65 6,31 0,52 0,29 0,19 1,22 2,29 4,21 1,56 
    2,00 x10-05 10,02 0,68 2,54 6,26 0,54 0,30 0,16 1,22 2,13 3,97 1,68 
    2,40 x10-05 12,02 0,62 2,41 6,12 0,59 0,30 0,11 1,25 1,78 3,51 2,01 
    2,80 x10-05 14,02                     
    3,20 x10-05 16,00 0,59 2,13 5,88 0,61 0,29 0,09 1,21 1,54 3,12 2,33 
    3,60 x10-05 18,01 0,54 2,11 5,92 0,61 0,30 0,09 1,22 1,50 3,14 2,38 
                              
Table 1. Parameters obtained from the time-resolved measurements performed at 37 ºC. 
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Annex E. Example of data treatment. 
 
- Example of the data treatment (difference between raw sample, including Raman peak and its respective blank, to 
tobtain the sample) (RuC+HSa) 
 
A: raw sample (HSA-RuC, obtained directly from the fluorometer) 
B: blank samples (RuC, obtained directly from the fluorometer) 
C: data treated (difference between plots A and B) 
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